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The aim of this project was to develop chiral chalcogen-centered 
organocatalysis to effect asymmetric halocyclization reactions. 
Cinchona alkaloids derived thiocarbamate catalysts were developed in our lab, 
which have proved to be competent to conduct asymmetric 
bromolactonization reaction as well as bromoaminocyclization reaction. 
Inspired by these pioneer researches, the selenium analogues were constructed 
to test their capacity of asymmetric catalysis. And three generations of 
selenium catalysts have been developed: cyclic selenourea type catalysts, 
cinchonine derived selenocarbamate catalysts, and cyclic X-Se-X type 
catalysts. 
While only appreciable ee can be achieved when the selenium catalysts was 
used to conduct asymmetric halolactonization reactions, good ees were 
obtained when sulfonamide substrates was used. And when the trisubstituted 
unsaturated sulfonamide substrates were used, up to 95% ee and high yield 
were achieved, the enantioenriched pyrrolidine products can undergo 
rearrangement to yield 2,3-disubstituted piperidines with excellent 
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Chapter I: Introduction of halocyclization reaction 
1.1 The history of the reaction between halogen and olefin 
1.1.1 Bromonium ion Vs β-halocarbonium 
The halocyclization reaction of olefins is an amazing transformation for its 
mechanism study as well as its versatility in constructing synthetically useful 
and bioactive molecules.  
The reaction between halogens and alkenes (1) has been discovered long time 
ago, and a detailed experimental procedure can be found in literature as early 
as 1851
1
. As the trans type product (4) was dominant in the solvent used 
reaction, the simple one-step mechanism was ruled out, and the β-
halocarbonium ion intermediate (2) was proposed by Robinson
2
 (Scheme 1.1), 
which was formed by the nucleophilic attack of ethylenic linkage to the 
induced “cationoid” bromine; to explain the observations that at least 80% of 
the halogenations reaction was underwent in the trans pattern, it was 
postulated that the rate of the attack of the halide anion to β-halocarbonium 




Scheme 1.1 β-Halocarbonium ion intermediate proposed by Robinson. 
Reasoning that given the halo atom at the β position of the carbonium cation, 
there was great possibility that one of the three electron pairs of the halo atom 
would be donated to the empty p orbital of the carbonium cation, leaving the 
halo atom bearing the positive charge, so a new mechanism model (6) was 
proposed by Robert and Kimball
3
 (Figure 1.1).  
 
Figure 1.1 Cyclic bromonium intermediate proposed by Robert and Kimball. 
But considering the difference between the ionization energy of carbon (11.22 
v) and that of a halogen (11.80 v for bromine) is so small, they stated that the 
actually structure of the ion should be intermediate between a halonium and β-
halocarbonium ion, like the canonical forms in a resonance of molecule. And 
the possibility that carbon-carbon bond would rotate still exists, if the 
repulsion of between R1 and R3 (or R2 and R4) is big enough, which had been 







Scheme 1.2 Trans-addition of Br2 to maleate ion. 
The ambiguity of this model however intrigued great interest among the 
research colleagues, which lasted several decades. 
1.1.1.1 Evidences from the stereochemistry of products 
An unusual phenomenon was observed by Winstein and Lucas
5
 that when 
subject to fuming aqueous hydrogen bromide, dl-2,3-dibromo-butane (20) was 
produced from meso-2,3-diacetoxybutane (11), while meso-2,3-dibromobutane 
(22) was produced from dl-2,3-diacetoxybutane (15). 
Further study revealed that the corresponding 3-bromo-2-butanol (14) should 
be the key intermediate in this reaction
6




Scheme 1.3 dl-threo-3-Bromo-2-butanol produced from meso-2,3-
diacetoxybutane under the condition of fuming aqueous hydrogen bromide. 
 
So under the acidic conditions one of the acetyl groups in meso-2,3-
diacetoxybutane (11) was removed (producing 12), followed by the SN2 
reaction with bromide anion (producing 13), the mono-acetate was then 
further hydrolyzed to produce the dl-threo-3-bromo-2-butanol (14). In the 
same fashion dl-erythro-3-bromo-2-butanol (18) can be produced from dl-2,3-
diacetoxy-butane (15) (Scheme 1.4). 
 
Scheme 1.4 dl-erythro-3-bromo-2-butanol can be produced from dl-2,3-




Detailed scrutiny about the transformation from 3-bromo-2-butanol to 2,3-
dibromobutane provide a solid evidence that a stable bromonium must 
participate in the reaction
7,8
 (Scheme 1.5, Scheme 1.6).  
 
Scheme 1.5 dl-2,3-Dibromo-butane produced from meso-2,3-diacetoxybutane. 
 
 
Scheme 1.6 meso-2,3-Dibromobutane produced from dl-2,3-diacetoxybutane. 
If the β-bromocarboniums (23, 24) participated instead, a totally different 
result should be obtained (Scheme 1.7).  
 
Scheme 1.7 Different result obtained if β-bromocarboniums were engaged. 
The reactions of trans- 1,2-dibromocyclohexane (25), dl- and meso-2,3-di-
bromobutane (30), with silver acetate in dry acetic acid, produced trans- 1,2-
diacetoxycyclohexane (29), dl- and meso-2,3-diacetoxybutane respectively 
(34)
9
. Again the retention of the configuration was ascribed to even number of 
6 
 
Walden inversions due to the neighbouring group participation, first of which 
led to the formation of bromonium ion (Scheme 1.8, Scheme 1.9).  
 
Scheme 1.8 Reaction of trans-1,2-dibromocyclohexane with silver acetate in 




Scheme 1.9 Reaction of meso-2,3-dibromobutane with silver acetate in dry 
acetic acid. 
 
To investigate the behavior of analogous dichloride, stilbene dichlorides were 
treated with silver acetate in acetic acid
10
. And it was puzzling to observe that 
the same product was produced from meso-dichloride (35) and dl-dichloride 
(37) (Scheme 1.10). This was explained by the fact that trans relationship of 
the two phenyl rings was preferred in the stable conformation of stilbene, so 
for the dl-dichloride (37) the formation of a stable chloronium ion was not 
favored due to the cis relationship or the two chlorine atoms to each other, 
which was also underpinned by the observation that dl-dichloride had bigger 
7 
 
dipole moment value than that of meso isomer
11
; the special position of the 
carbon atom in the reaction site-benzylic position-also facilitate the 
disjunction of chlorine ion compared with simple alkyl chloride. This 
observation however indicate that the formation of halonium ion is dependent 
on the halogen species as well as substrate, though more experiment data is 
required for a solid conclusion.   
 
Scheme 1.10 The reaction of stilbene dichlorides with silver acetate in acetic 
acid. 
 
In the studies of neighboring group effect
12
, the rate of solvolysis in anhydrous 
acetic acid of trans-2-iodocyclohexyl p-toluenesulfonate, 2-bromocyclohexyl 
p-bromobenzenesulfon-ate (cis and trans), and 2-chlorocyclohexyl p-
bromobenzenesulfonate (cis and trans) were measured
13
. Contrasting 
difference was observed between cis and trans isomers, especially for the 
bromide analogues. The distinct difference indicated that the trans isomer can 
provide special driving force that the corresponding cis isomer cannot, and the 
8 
 
authors ascribe the driving force to the formation of halonium ions. So in this 
2-halocyclohexyl benzenesulfonate system, iodonium ion can be constructed 
most easily, bromonium ranks second, while due to the little difference 
between cis and trans chloride analogues, the involvement of chloronium ion 




In the study of addition of bromochloride to stilbene, Buckles and Long
15
 
found that from trans-stilbene (40), all the product was obtained through the 
trans addition pathway, while from the cis-stilbene (41) only around three 
fourths product was obtained through the same pathway (Scheme 1.11). This 
result suggested that the stability of bromonium ion would be undermined by 
another force such as the steric repulsion between the two phenyl groups in 
cis-stilbene
16
; also the relatively stable benzyl carbonium would make the 
other pathway possible in the reaction, which make the existence of 




Scheme 1.11 The reaction of trans and cis stilbene with BrCl. 
The authors also investigated the reaction of stilbene dibromide (dl (45) and 
meso (46)) with stannic chloride, similar result was obtained as the dichloride 
analogues
10
 (Scheme 1.12).     
 
Scheme 1.12 The reaction of dl and meso stilbene dibromide with stannic 
chloride. 
 
In the addition reaction to methylenecyclodecane (48) with various reagents
17
, 
elimination reaction was usually accompanied for the relief of the transannular 
strain in the medium-sized ring, for example, the addition of HBr, and HOCl 
cannot afford the expected normal addition product, the elimination of 
hydrogen occurred instead, after the first electrophilic attack to the 
methylenecyclodecane and right before the nucleophilic attack, so that two 
trigonal carbons were introduced to the medium-sized ring, indicating that a 
tertiary carbonium ion was preferred in the process of reaction (Scheme 1.13).   
 





However, when HOBr was used, no elimination reaction was observed, and 
the water molecule attacked the primary carbon due to the special geometry of 
the intermediate
18
. And the relatively stable bromonium ion was ascribed for 
this contrasting result (Scheme 1.14). 
 
Scheme 1.14 The reaction of methylenecyclodecane with HOBr, H2O. 
Fahey and Schneider studied the addition of bromine to trans (52) and cis (53) 
1-phenylpropene
19
, and the reactions were found to be not stereo-specific. 
From trans isomer (52), the ratio of erythro (54): threo (55) product was 88 : 
12, and from cis (53) isomer, the ratio was 17 : 83 (Scheme 1.15). 
 
Scheme 1.15 The addition of bromine to trans and cis 1-phenylpropene. 
11 
 
The authors argued that the collapse of a weakly bridged bromonium ion (56) 
and the rotation about the C1-C2 bond must happen, for the cis addition of Br
-
 
to the benzylic carbonium in a direction parallel to the first formed C-Br bond 
was not preferred (Scheme 1.16). 
 
Scheme 1.16 The collapse of bromonium ion. 
The addition reaction of bromine to a series of styrene derivatives in acetic 
acid were studied by Rolston and Yates
20
. Similar stereochemistry of 
dibromide product was found as the research of Fahey and Schneider
19
; while 
strereospecific result was obtained for the  1-acetoxy-2-bromo product, which 
was explained due to the availability of the acetate anion in the opposite side 
of the newly formed bromonium ion, while reorientation was needed for the 
equivalent bromine anion. 
However syn addition of halogens to indene was observed by Heasley, et al
21
. 
In aprotic solvent, dichloromethane for example, a substantial amount of cis 
product was obtained: 30% from the reaction with bromine, 20% from 
bromine chloride, 40% from chlorine, 20% from acetyl hypobromite, and 40% 
from acetyl hypochlorite.  Due to the rigid five-member ring skeleton, the 
authors ascribe the syn addition to the direct syn collapse of ion pairs, instead 
12 
 
of by carbon-carbon bond rotation followed by anti collapse as proposed by 
Fahey and Schneider
19
 (Scheme 1.17). 
 
Scheme 1.17 Possible pathways of the attack of Y
-
. 
It was also found that a combination of low polarity solvent and higher 
halogen concentration could lead to more syn adduct, and a concerted 
mechanism was proposed (Scheme 1.18). 
 
Scheme 1.18 Concerted mechanism. 
While the electrophilic addition to indenone occurred with much higher 
stereoselectivity, and the carbonyl group connected to the double bond was 
believed to stabilize the halonium. 
Besides the stabilization from benzene ring, other functional group can also 
serve similarly, for example, a remote sulfone group was found to be able to 
13 
 
stabilize β-bromocarbonium through Coulomb interaction22. So from the 
bicyclic sulphone (58), equal amount of trans (61) and cis (62) adduct can be 
obtained (Scheme 1.19). 
 
Scheme 1.19 The addition of Br2 to bicyclic sulphone (58). 







) in the presence of nucleophile (H2O and H2S), the 
stereochemistry of the product,  3-halobutan-2-ols (or thiols) implied that the 
stability of the intermediate, cyclic 2,3-butene halonium ions, depends mainly 
on the nature of the halogen involved: bromonium ion was more stable than 
chloronium, while the existence of fluronium ion was not indicated
23
. 
To study the stability of bromonium and iodonium ion, β-deuteriostyrene was 






Scheme 1.20 The reaction of cis-β-deuteriostyrene with XN3. 
And the reaction of cis-β-deuteriostyrene (63) with iodine azide in polar 
solvent gave only threo product (67), while with bromine azide 1 : 1 mixture 
of erythro (68) and threo product (67) was obtained, which indicated that the 
iodonium ion was stable even in the existence of a possible relatively stable 
benzyl cation, while bromonium ion was not stable enough to compete with 
benzyl cation (Scheme 1.20). 
The chlorination of olefins in nonpolar solvents without radical inhibitors was 
proved to undergo through radical process; to study the ionic process of this 
reaction, oxygen was introduced to the reaction system to suppress the radical 
pathway
25
. It was found that both cis and trans-2-butenes produced the 
corresponding dichloride via trans addition fashion. 
The chlorination of 2-butenes and 1-phenylpropenes gave contrasting results
26
. 
The chlorination of cis- or trans-2-butene in acetic acid yields 2,3-
dichlorobutane and 3-chloro-2-butyl acetate by an exclusively trans-addition 
process. While the product from the reaction of cis- or trans-1-phenylpropenes 
and chlorine indicated that a non-stereospecific process was underwent. And 
15 
 
the different product distribution of the cis and trans isomers suggested that 
the rate of rotation about carbon-carbon single bonds can be comparable to the 
rate of ion-pair collapse; in this way, each conformer could collapse to 
products at a different rate and interconversion of the conformers would occur 
at different competing rates.   
With linear alkenes, the existence as well as stability of chloronium ion can be 
both observed for even chlorination reactions
27
. The reaction of  trans-di-t-
butylethylene with chlorine in carbon tetrachloride in the presence of oxygen 
produced meso-3,4-dichloro-2,2,5,5-tetramethylhexane, as well as a 
rearranged product, which was derived from the anti attack of methyl group to 
the chloronium ion. The reaction of cis-di-t-butylethylene, which was believed 
to be destabilized by the steric repulsion of the two t-butyl groups by 9.3 kcal 
relative to the trans isomer
28
, gave stereospecific dichloride only, the dl-3,4-
dichloro-2,2,5,5-tetramethylhexane.         
1.1.1.2 Evidences from direct observation of the halonium ion NMR 
spectrum 
Since the first proposal of Roberts and Kimball, in the following three decades, 
the supports mainly came from the stereochemistry of products, or the 
neighboring group effect of halogens, especially iodine and bromine. The first 
direct experimental observation of halonium ions in solution was contributed 
by Olah and Bollinger
29
 (Scheme 1.21). When 2,3-dihalo-2,3-dimethylbutanes 
(69, 70, 72, 73, 75) were ionized in antimony penta-fluoride-sulfur dioxide 
solution at -60 
o
C, stable solutions of tetramethylethylenehalonium ions can be 
observed with chlorine (71), bromine (74), and iodine (76)  acting as donor-
16 
 
participating atoms. And the above mentioned halonium ions were rather 
stable: after several weeks at -78 
o
C, no decomposition was noted. 
 
Scheme 1.21 The first direct experimental observation of halonium ions in 
solution. 
 
While for fluoride, only β-fluorocarbonium ion was observed even the 
temperature was decreased to -90 
o
C (Scheme 1.22). And the stability of this 
β-fluorocarbonium ion was poor compared with the haloniums:  it would 
totally decompose at the temperature of dry ice within one week.  
 
Scheme 1.22 β-Fluorocarbonium ion. 
1.1.1.3 Evidences from X-ray analysis of stable halonium ions 
Another breakthrough appeared shortly after the above discovery, Wynberg 
and coworkers
30
 found that a yellow solid was obtained when 
adamantylideneadamantane (80) was treated with bromine in carbon 
tetrachloride at room temperature. The new compound was poorly dissolved in 
nonpolar solvents such as carbon tetrachloride, hexane, or ether; and the 
17 
 
attempts to crystallize it from polar solvents (acetone, or dimethylsulfoxide) 
only leaded to release of adamantylideneadamantane and bromine. Several 
tests were conducted: (1), the product can oxidize potassium iodide, and 
adamantylideneadamantane can be recovered; (2) microanalysis showed that 
the composition of the new compound should be C20H28Br4; (3) in the mass 
spectrum of new compound, peaks such as m/z 268, 79, 81, 158, 160, and 162 
can be found, indicating that the existence of the adamantylideneadamantane 
moiety, whose MW is 268, as well as Bromine. Based on all of the above 
observation the authors proposed that the product should be a stable 
bromonium ion (81) (Scheme 1.23).  
 
Scheme 1.23 The first stable solid state bromonium ion proposed by Wynberg 
and coworkers. 
 
While no stable halonium can be obtained by the reaction of   analogous 
chlorine and adamantylideneadamantane at room temperature
31
, but white 
solid can be obtained when the reaction was performed at -20 
o
C, and when 
the temperature increased only the adamantylideneadamantane and chlorinated 
adamantylidene-adamantane were obtained.   
Olah and coworkers investigated the product of adamantylidene-adamantane 
with bromine, chlorine, and cyanogen iodide
32





NMR data obtained, as well as other characteristics, for example, the bromine 
complex delivered bromine to cyclohexene or 2,3-dimethyl-2-butene 
18 
 
irreversibly, lost bromine in high vacuum (10
-8
 Torr) with the parent olefin left, 
et al, the complexes were defined as two-electron, three-centered bonded π 
complexes, instead of three-membered ring σ complexes (halonium ion).   
The thermal stable chloronium salts were claimed to be prepared by the 
reaction of adamantylideneadamantane with SbCl5 and MoOCl4 respectively
33
. 
And the stability of such complexes suggested the feasibility of X-ray study of 
this species.  
The first single-crystal X-ray analysis of bromonium ion was accomplished by 
Brown and co-workers in 1985
34
. The information represented by the X-ray 
offered important insight about the nature of the complex, for example, the 
bromine atom is positioned slightly asymmetrically with respect to the two 
carbon atoms which form the three-membered ring: C1-Br1, 2.116 (6) Å; C11-
Br1, 2.194 (6) Å. These distances are slightly longer than normal C-Br single 
bonds which usually fall in the range 1.93-2.04 Å. The C-C bond of the three-
membered ring is 1.497 (8) Å which is slightly shorter than that for a normal 
C-C single bond (1.54 Å.) but very much longer than the double bond in 
adamantylideneadamantane (1.336 Å). The dihedral angle between the planes 
C1-C2-C8 and C11-C12-C18 is 32.9
o
 which indicates that the two adamantane 
moieties are each bent away from the Br1 atom by a significant amount 
(Figure 1.2). And all the above mentioned data have contrast differences with 
the accepted π complex formed between olefin and metal, while are similar to 




Figure 1.2 The first single-crystal X-ray analysis of bromonium ion. 
Later it was found that the counterion Br3
-
 could be replaced by a nearly 
nonnucleophilic triflate counterion
35
. And the triflate salts of bromonium and 
iodonium ions of adamantylideneadamantane were accomplished in 1994
36
. 
The main difference between the triflate salt and the corresponding Br3
-
 salt is 
the symmetry of the bromonium three-membered ring, and the former one is 
more symmetric than the later one, the bond length of Br1-C10 is 2.118 (10) Å, 
Br1-C20 is 2.136 (10) Å in triflate salt, compared to 2.116 (6) Å, and 2.194 (6) 
Å in Br3
-
 slat. And the bond length of I-C10 is 2.362 (6) Å, I-C20 is 2.338 (6) Å. 




Figure 1.3 The stable bromonium ion triflate salt. 
The unique structure of this halonium ion also offered a very precious 
opportunity to investigate in detail the mechanism of first steps of the 
halogenation reactions for it hampering rearside nucleophilic attack of the 
counteranion.  
1.1.2 Charge transfer complexes (CTC) 
Besides the halonium ion or β-halocarbonium ion as the key intermediates in 
halogenation reactions, another species involved in the same process drawing 
great interest was charge transfer complexes (CTC) formed between halogen 
molecular and olefins. Charge transfer complexes have long been proposed to 
21 
 
be formed in the chlorination reactions
37




The role of the CTC in reactions between bromine and olefins were studied by 
spectrokinetic analysis
39
. And a AdEC1 pathway was proposed by Dubois and 
coworkers due to the sensitivity to solvent effect
40
. Further investigation was 
performed by secondary solvent isotope effect, and the hydroxylic solvents 
were suggested to facilitate the reaction by stabilizing the transitional state 
through hydrogen bonding
41
 (Scheme 1.24).  
 
Scheme 1.24 The collapse of CTC to bromonium ion facilitated by hydroxylic 
solvents. 
 
In a kinetic study of simple olefin bromination reactions in carbon 
tetrachloride, it was observed that the apparent third-order rate constants 
changed systematically with the olefin-bromine composition, while the 
individual reaction rates were reproducible. Gebelein and Frederick ascribed 
this phenomenon to the participation of complex formation in the reaction 
pathway
42
. And the enhanced reactivity of (Z)-3-hexene over (E)-4-octene 
under competitive conditions, which was consistent with complex formation 
assuming that (Z)-alkene complexes form more readily than (E)-alkene 
complexes, further confirmed the existence of olefin-bromine complex. 
22 
 
The equation has been established to describe the rate of bromine addition to 
general olefins, which contains a variety of kinetic terms depending on the 
concentration of Br2 and presence of Br
-
 (Scheme 1.25). 
                                       
                 
    
Scheme 1.25 The equation describing the rate of the reaction between bromine 
and olefin.  
 
The importance of    at higher bromine concentration was first introduced by 
Robertson and coworkers
43-46
. The term    also dominates for reactions 
conducted in reduced polarity solvents, such as chloroform or chlorobenzene
47
. 
While in polar solvent, such as acetic acid and water and when the 
concentration of Br2 was less than 10
-3
 M, the term    dominates
45
. And when 




As the reaction kinetics has important bearing on the related mechanism, the 
charge transfer complexes have been used to interpret the observed third-rate 
laws (second-order in bromine). Thus, the CTC was formed through the initial 
electrophilic attack of bromine to alkene, followed by the production of 
bromonium or β-bromocarbonium with the cleavage of bromine-bromine bond 
in the CTC assisted by another molecular of bromine
54,55
. 
The first systematical study of CTC was conducted by Bellucci and 
coworkers
56
. Unlike the previously reported records on the observation of 
CTC, which were conducted under reduced reactivity conditions, for example, 
deactivated substrate- crotonic acid, was reported to form a CTC with bromine 
in 1,2-dichloroethane, with a formation constant Kf of 0.08 (8) M
-1
, which was 
23 
 
too low to judge fairly whether a CTC was form or not
57
; or the CTCs were 





et al, in which circumstance the molecular mechanism was suspected to be 
favoured instead of ionic mechanism. Cyclohexene was treated with bromine 
in 1,2-dichloroethane in 15-35
o
C temperature range. And the formation 
constant Kf of 0.47 (8) M
-1
 was measured. 
Brown, Bellucci, and coworkers then investigated the solution behaviour of 
the complex formed from adamantylideneadamantane and bromine
59
, it was 
proposed that in 1,2-dichIoroethane solution an equilibrium is instantaneously 
established among 1:1, 1:2, and 1:3 olefin-Br2 aggregates (Scheme 1.26). 
 
Scheme 1.26 The equilibrium between 80 and Br2 in 1,2-dichloroethane 
proposed by Brown, Bellucci, and coworkers. 
 
And a picture showing possible pathways in ionic bromination mechanisms 




Scheme 1.27 A detailed picture showing possible pathways in ionic 
bromination. 
 
1.1.3 Degenerate halogen exchange of halonium ion 
1.1.3.1 Evidences from the formation of crossed products 
Inspired by the regeneration of bromine and adamantylidene-adamantane from 
the complex formed by the former two components, Brown and coworkers 
investigated the reversiblility of normal alkenes
60
 (Scheme 1.28). trans-2-
Bromo-l-[((4-bromophenyl)sulfonyl)oxy]-cyclohexene (90) and -cyclopentane 
were subject to glacial acetic acid containing bromide and a scavenger olefin 
(cyclopentene (92) for the former and cyclohexene for the later), and free 
25 
 
molecular bromine was generated which was evidenced by the formation of 
crossed products (97, 98).  
 
Scheme 1.28 Crossed products formed by the regeneration of Br2 from 
bromonium ion and bromide. 
 
Bellucci and coworkers also investigate the same topic by reacting erythro- 
(99) and threo- 2-bromo- 1,2-diphenylethanol with gaseous HBr in chloroform 
and 1,2-dichloroehthane. Besides the main product obtained as 1,2-dibromo- 
1,2-diphenylethane (103), substantial amount of trans-stilbene (104) was 
obtained, indicating the reversibility of the formation of bromonium ion
61
 




Scheme 1.29 The generation of trans stilbene via the corresponding 
bromonium ion. 
 
Similar result was observed that the bromonium ion intermediate generated 
from the reaction of trans-10-bromo-10,11-dihydro-11-hydroxy-5H-
dibenz[b,f]azepine-5-carbonyl chloride (105) with gaseous HBr in 1,2-
dichloroethane, chloroform, or carbon tetrachloride can either collapse to 
trans-10,11-dibromo- 10,11-dihydro-5H-dibenz[b,f]aze-pine-5-carbonyl 
chloride (106) or release molecular bromine, to give 5H-dibenz[b,f]azepine-5-
carbonyl chloride (107)
62
 (Scheme 1.30).  
Scheme 1.30 The generation of 107 from the corresponding bromohydrin. 
 
More interesting phenomenon was observed when the trans-dibromide (106) 
was subject to cis-stilbene (108) in acetonitrile, 5H-dibenz[b,f]aze-pine-5-
27 
 
carbonyl (107) was recovered with the formation of meso- and d,l-1,2-
dibromo- 1,2-diphenylethane (109), the first case of bromine transfer from a 
dibromide molecular to another type of alkene (Scheme 1.31). 
 
Scheme 1.31 Bromine transfer from dibromide 106 to cis-stilbene. 
 
1.1.3.2 Evidences from direct observation of stable halonium ion NMR 
spectrum 
The phenomenon of reversibility of the bromonium formation was also 




C-NMR spectrum of the triflate 
salt at -80 
o
C can give distinct signals of C8, 8’, 10, 10’, which was downfield 
from their counterparts C4, 4’, 9, 9’ due to the presence of bromine atom; similar 
result was observed for the signals of C7, 7’ and C5, 5’. But when a small amount 
of the parent olefin was added, the peaks for C8, 8’, 10, 10’ and C4, 4’, 9, 9’, those for 
C7, 7’ and C5, 5’ began to broaden, then coalesce, and finally give a single 
narrow line for C4, 4’, 8, 8’, 9, 9’, 10, 10’ and C5, 5’, 7, 7’ respectively as more olefin 
was added. And this result gave strong evidence for the exchange of 
bromonium ion (Scheme 1.32). 
 
Scheme 1.32 The degenerate bromine exchange of stable bromonium ion 110. 
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When nucleophiles were present intramolecularly, the received bromine ion 
would be trapped intramolecularly, and the reversibility of the bromonium ion 
would be clearly judged. And this idea was utilized by brown and coworkers 
to further manifest the concept mentioned previously. And the role of the 
stable bromonium ion or iodonium ion were to some extent like halogen 





1.2 Halocyclization reactions 
When nucleophiles such as carboxylic acid, alcohol, or amide attack the 
halonium ions intramolecularly, products like halolactones, halocycloethers, 
and halolactams would be obtained respectively, which form a large library of 
bioactive products or valuable synthetic intermediates. 
1.2.1 Racemic halocyclization reactions 
1.2.1.1 Racemic halolactonization 
The first halogen-initiated intramolecular cyclizations studied were 
halolactonizations, specifically bromolactonizations that were independently 
investigated by Fittig and Stobbe in the late 19th century
65-70
. The iodine 
analogue of this reaction was discovered soon after
71-73
, and quickly became 
the halolactonization of choice due to the versatility of the C–I bond 
transformation in leading to other functionality. It was not until over 20 years 
later that chlorolactonization was disclosed
74
, and as is the case for all classes 
29 
 
of halonium-induced cyclizations, it is the chlorine variant that is the least 
frequently investigated. Fluorine is barely mentioned in the literature of 
electrophilic halocyclizations, while in the asymmetric version of this series of 
reactions, fluorocyclization appeared occasionally. 
As mentioned above, iodolactonization was discovered relatively early; in the 
early 20th century, it was usually used in titration analysis to determine the 
concentration of unsaturated fatty acid isomers based on their different rates of 
reaction with a solution of I2 and KI in aqueous NaHCO3
71-73
. A detailed 
mechanistic description of the process was not disclosed until 1927, when 
Reginald Linstead and Cecil May hypothesized that iodine activation of a 
double bond precedes the attack by a carboxylate nucleophile
75
. Nearly 30 
years later, van Tamelen and Shamma further refined that mechanism by 
introducing an iodonium ion to explicate the relative rates of 5-exo and 6-endo 
iodolactonizations
76
. Soon later, Klein confirmed van Tamelen’s hypothesis by 
disclosing that the lactones formed in these reactions have their iodine atom 
and ester moiety in a trans orientation
77
. 
As regard to the reagents that can effect these reactions, for nearly all of the 
first century since its discovery iodolactonization was conducted using the 
original conditions devised by Bougault
71-73
: I2 and KI added to a solution of 
the unsaturated acid in aqueous NaHCO3 solution. In 1953, it was published 
that ICN in chloroform could also accomplish iodolactonizations, releasing 
one equivalent of HCN after the reactions
78




Scheme 1.33 Iodolactonization using ICN as reagent. 
Developments of more practical and environment friendly conditions appeared 
in the 1970s and the following decades. For example, in 1972, Barnett stated 
that if iodolactonization reaction was conducted using I2 in a diphase system 
of Et2O and aqueous NaHCO3, it was possible to produce the kinetic 
cyclization product (one which is not typically the same as the thermodynamic 
product)
79,80
 (Scheme 1.34).  
 
Scheme 1.34 Iodolactonization prefer kinetic cyclization product in biphasic 
system. 
 
Two years later, Cambie and co-workers stated that the use of thallium(I) 
carboxylates as starting materials gave higher yields of the iodolactone 
products than that of the analogous sodium salts
81
 (Scheme 1.35).  
 





No significant changes have been performed concerning the iodine source 
maybe due to the relative availability of iodine element, until 1983 Cook and 
coworkers reported that N-iodosuccinimide (NIS) is a highly competent 
reagent for iodolactonization
82
 (Table 1.1).  
Table 1.1 Halolactonization performed with N-haloimides. 
 
 
Rousseau then disclosed in early 1990s that bis(collidine)iodonium 
hexafluorophosphate, (coll)2IPF6, could be used to construct macrocyclic 
iodolactones, on the condition that certain structural motifs like oxygen atoms, 
gem-dimethyl substituents, alkynes, or aromatic rings were incorporated into 
the chain between the alkene and carboxyl groups




Scheme 1.36 Macrocyclic iodolactones formed by using (coll)2IPF6 as iodine 
source. 
 
Other reaction systems have also proven efficient to perform such kind of 
cyclizations. For example, NaI accompanied by Pb(OAc)4 afforded a number 
of iodolactones
88
, though the endo vs exo selectivity was poor where mixtures 
of products are possible (Scheme 1.37). 
 
Scheme 1.37 Iodolactonization using a combination of NaI and Pb(OAc)4. 
In addition, Taguchi and co-workers discovered that substrates with a protonic 
group (OH or NHTs) near the carboxylate nucleophile could lead to cyclic 
products with high cis selectivity by using a Ti(IV) Lewis acid to fix the 
substrate prior to the attack of iodine source
89
 (Scheme 1.38).  
 
Scheme 1.38 Iodolactonization using Ti(IV) Lewis acid. 
Recently, in a systematic study, Denmark’s group investigated the behaviour 
of various Lewis base catalysts in conjunction with NIS concerning the yield, 
region- and stereo-selectivity of the cyclic products
90
 (Scheme 1.39). And the 
concept behind was the theory emphasizing that Lewis base activation of 






Scheme 1.39 Halolactonization catalyzed by Lewis base. 
The lighter element next to iodine in halogen family is bromine, and the very 
first reaction conditions (initiated by Stobbe and Fittig)
65-70
 utilized Br2 in 
halogenated solvents, rather than the aqueous ones that were later adopted for 
the first iodolactonization reactions. The first mechanistic explanation of the 
bromolactonization reaction was reported by Arnold’s group in 195392 
followed by more detailed study by Barnett and McKenna in 1971, whose 
final conclusions were overall the same as those for iodolactonization
93
.  
As for the reaction conditions and halogen source reagents, those of which that 
were utilized in iodolactonization reactions can be applied to the bromine 
version most of the time.  
So the bromine type N-halosuccinimides such as NBS and NBP proved to be 




 and in 
situ generation of Br
+
 via oxidation of inorganic bromide by Pb(OAc)4 also 
proved feasible
88
. And more interestingly, the bromination reagent 
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(coll)2BrPF6 explored by  Rousseau’s group can be used to cyclize α,β-




Recent investigations mostly focus on the improvement of the behaviour of N-
halosuccinimides such as NBS, which was observed to be effect the 
cyclization reaction slowly when used alone.
94,96-98
 And a variety of reagents 
have been used, such as diselenides
99





, and 3 Å molecular sieves
98
.  
Due to the relatively lower reactivity of the chloride product in the cyclization 
reactions, these reactions were less studied than the two discussed above. The 
first publication of chlorolactonization appeared in the year 1932, in which 
Bloomfield and Farmer mentioned that a combination of aqueous HOCl and 
CaCl2 could initiate  chlorolactonization reactions
74
. Nearly twenty years later, 
a solution of Cl2 in CHCl3 was used to conduct a key chlorolactonization step 
for the preparation of allo-patulin
101
 (Scheme 1.40).  
 
Scheme 1.40 Chlorolactonization using chlorine in chloroform. 
And a detailed study on the stereochemistry as well as the mechanism of this 
reaction was disclosed by Berti in 1958
102
. Later on, more practical procedures 
were developed, such as the use of the chloramine-T
103
 (Scheme 1.41) and 







Scheme 1.41 Chlorolactonization using chloramine-T. 
 
Scheme 1.42 Chlorolactonization using NaOCl and CuCl2·2H2O. 
1.2.1.2 Racemic haloetherification 
Oxetane, tetrahydrofuran, tetrahydropyran, and even larger ring systems can 
be formed during the haloetherification reactions, which make the later a 
highly useful procedure in organic synthesis.  
The first report of iodoetherification reaction appeared in a 1967 by Williams, 
wherein 4-pentenyl alcohol was treated with I2 in aqueous KI solution yielded 
the 5-exo tetrahydrofuran product almost exclusively
105,106
 (Scheme 1.43).  
 
Scheme 1.43 Iodoetherification using I2 and aqueous KI. 
A more detailed study was published in 1985, wherein Yoshida and coworkers 
cyclized a variety of unsaturated alcohols under several iodoetherification 
conditions [I2–NaHCO3, NIS, or (coll)2IClO4]. The yields and distribution of 
the resultant cyclic ethers were then compared among those systems. And it 





It was demonstrated that in situ generation of X
+
 via inorganic halide salt with 




Improving the rate of iodoetherifications has been the target of more recent 
investigations, which have largely focused on using NIS in combination with a 
catalytic additive. Important results in this area include Morgan’s discovery 
that the addition of 3 mol % (dppf)PdCl2 leading to rapid cyclization of 
(bishomo)allyl alcohols at room temperature in moderate to high yields
108
 
(Scheme 1.44).  
 
Scheme 1.44 Iodoetherification using (dppf)PdCl2 as catalyst. 
Meanswhile, Denmark’s Lewis base activation concept proved competent for 




Scheme 1.45 Iodoetherification using sulphur catalyst. 
 
And the authors envisaged that use of either a chiral diphosphine ligand 
(Morgan) or chiral Lewis base (Denmark) could potentially render these 
reactions enantioselective.  
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As for the Br version of this process, early reports of the reactions generally 
used Br2 in an organic solvent along with base (usually quinoline or 
KOH)
109,110
. Then, several reagents have been shown to effect this reaction. 
For example, two natural product total syntheses in 1988 and 1993 featured 
2,4,4,6-tetrabromo-2,5-cyclohexadienone (TBCO) as the bromine source for 
the etherification reaction
111-113




Scheme 1.46 TBCO utilized in etherification reactions for total synthesis. 
Py2BrX salts were studied systematically in Brown’s group
114
, by whom the 
asymmetric version had also been attempted
115
. Another interesting discovery 
was that cyclization of allylic alcohols could be furnished with (coll)2BrPF6 to 
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produce the 4-endo cyclization products in moderate yields
116
; while these 
trans oxetanes only form with an aryl group at the 3 position of the allylic 
alcohol, whereas with alkyl groups, rearrangements would occur to form 
larger, more stable cyclic ethers (Scheme 1.47).  
 
Scheme 1.47 The bromoetherification of allylic alcohol. 
The Lewis bases catalyzed bromoetherification reactions published by 
Denmark’s group can give the products with good yields and excellent 
selectivities
90
 (Scheme 1.48). 
 
Scheme 1.48 Bromoetherification catalyzed by Lewis base. 
 
1.2.1.3 Racemic haloamination 
When this cyclization process was performed using another species of 
intramolecular nucleophile-Nitrogen, the products constructed would be 
aziridines, pyrrolidines, piperidines, et al, which are as valuable as the oxygen 
analogues.  
However, the investigation in this direction is not so straightforward, 
especially when the lactams were the desired products, due to the inherently 
higher electronegativity of oxygen relative to nitrogen
117
. So the earlier 
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explorations to construct halolactams adopted kinds of procedures to suppress 
the nucleophilicity of oxygen while at the same time enhance that of the 
nitrogen.  
Durst and coworkers circumvented the above mentioned problem by choosing 
a substrate that could not favour the oxygen attack geometrically, the product 
of which pathway could only lead to exo seven-membered ring or endo eight-
membered ring product, while the nitrogen attack gave the correspondingly 
five or six-membered ring product in theory. So 4-homoallyl-β-lactams was 
treated with I2 and Na2CO3 in CH2Cl2
118
, and the nitrogen-cyclized product 
was obtained in moderate yield (Scheme 1.49). 
 
Scheme 1.49 The geometrically favoured nitrogen-cyclized product. 
Later it was reported by Ganem and coworkers that when a additional tosyl 
group was introduced to the nitrogen atom, the nucleophilicity competition 
would readily favour the side of nitrogen, and the lactam products would be 
obtained exclusively
119
 (Scheme 1.50).  
 
Scheme 1.50 Enhanced nucleophilicity by the incorporation of Ts. 
Years later, the same concept was utilized by Rajendra and coworkers, while 
O-Cbz hydroxamates instead of N-tosylamides was adopted
120
. So after the 
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treatment of Br2 and potassium in aqueous acetonitrile, the desired product can 
be obtained in moderate to good yield (Scheme 1.51). 
 
Scheme 1.51 Enhanced nucleophilicity by the incorporation of O-Cbz. 
Another method to cope this problem was to pre-protect the competitive 
oxygen atom, so the opportunity of the formation of the oxygen cyclized 
product was eliminated. Thus the silylation of both the oxygen and nitrogen of 
an amide in situ, followed by addition of I2, afforded the desired lactams in 
moderate to good yield
121,122
 (Scheme 1.52).  
 
Scheme 1.52 Construction of lactams through pre-protection of the oxygen. 
Other related modifications also appeared, for example, Brinkmeyer and 
coworkers disclosed the cyclization of both ureas and heteroaromatic-
substituted amides with NBS in 1989123 (Scheme 1.53).  
 
Scheme 1.53 Cyclization from urea type substrates. 
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Similarly, the halolactamization can be realized from urea as well as 
carbamate type substrates with stoichiometric CuBr2 and LiBr accompanied 
by catalytic Pd(OAc)2, and the advantage of this procedure is that the chloride 
version can be readily achieved simply by using the corresponding chloride 
salts (Scheme 1.54).  
 
Scheme 1.54 Cyclization from carbamate type substrates. 
Another interesting example is a tandem cyclization reaction from N-tosylurea 
substrates published by Widenhoefer’s group. So the bicyclic isourea product 
can be obtained under the condition of NIS in the presence of NaHCO3
124
. 
Moreover, bicyclic ureas were formed in good yields when AgOTf was added 
instead of NaHCO3 (Scheme 1.55).  
 
Scheme 1.55 The tandem cyclization from N-tosylurea substrates. 
Besides the above mentioned N nucleophile variants, N-protected unsaturated 
amines have also approved to be good substrates for nitrogen cyclization 
reactions. For example, allylic N-tosylamines was reported by Taguchi and 
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coworkers to be able to form aziridines upon treatment with I2 and t-BuOK in 
good yields
125-127
 (Scheme 1.56).  
 
Scheme 1.56 Aziridine formed from allylic N-tosylamine.  
Similarly, N-tosyl ortho-allylanilines were reported by Chemler and co-
workers to form a mixture of 5-exo- (indoline) and 6-endo- 
(tetrahydroquinoline) cyclization products in the presence of catalytic 
Pd(TFA)2 and stoichiometric CuBr2
128
 (Scheme 1.57).  
 
Scheme 1.57 Indoline and 4-H-quinoline from N-tosyl ortho-allylaniline. 
When Boc was used instead of Ts, similar result can be obtained. For example, 
3-iodoindoles can be produced from ortho-alkynylanilines using  Py2IBF4–
HBF4 as reagent
129
 (Scheme 1.58).  
 
Scheme 1.58 3-Iodoindole from ortho-alkynylaniline. 
In a similar pathway, palladium catalyst was used by Michael’s group to effect 
the 5-exo cyclization of N-Boc ortho-allylanilines with NCS as halogen 
source
130




Scheme 1.59 5-exo cyclization of N-Boc ortho-allylaniline. 





, were also reported to be able to cyclize to 
iodolactam products (Scheme 1.60).  
 
Scheme 1.60 Halocyclizations from non-amide substrates.  
 
1.2.2 Substrate-controlled halocyclization 
New stereogenic centre(s) would be formed after these cyclization reactions, 
and the efforts to obtain pure enantiomer have commenced since the eighties 
last century.   The first attempts to effect enantioselectivity were conducted 
through substrate control processes.  
The pioneer investigations of substrate-controlled asymmetric 
halolactonizations were conducted by Terashima’s research group, and L-
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proline was incorporated into the substrate and used as the nucleophile to 
induce enantioselectivity
133-135
 (Scheme 1.61).  
 
Scheme 1.61 The substrate-controlled bromolactonization using L-proline 
derivative as substrate. 
 
Since then other type of auxiliaries also have been successfully established, 
including oxazolidinones
136
 and pseudoephedrine-derived amides
137
. 
And the pioneer work was published in 1981, wherein Takano and coworkers 
subjected a chiral amide prepared from L-proline and a symmetric carboxylic 
acid to iodine in THF/H2O, and the desymmetrized product was obtained with 
16% ee
138
 (Scheme 1.62).  
 
Scheme 1.62 The seminal substrate-controlled iodolactonization using L-
proline as auxiliary. 
 
Soon later, various modifications had been done on the seminal procedure, 
mainly on the chiral auxiliary to improve the enantioselectivity. New 
auxiliaries include C2-symmetric auxiliaries
139,140
 (Scheme 1.63), sultams
141 
(Scheme 1.64), and even axially chiral amides
142








Scheme 1.64 Substrate-controlled iodolactonizations using sultams auxiliary. 
 
Scheme 1.65 Substrate-controlled iodolactonizations using axially chiral 
amide auxiliary. 
 
And the substrate-controlled cyclization of unsymmetrical substrates was 
investigated intensively within Kurth’s group in the early 1990s. α-Alkylation 
was conducted prior to iodolactonization high ee, and the subsequent 
iodolactonization reaction was completed with up to 99% de
143-146
.  
The analogous substrate-controlled haloetherification was less studied 
compare to the halolactonization ones. Investigations in Fraser-Reid’s group 
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used a glucose-derived chiral auxiliary, and the desired products can be 
obtained with up to 85% ee
147,148
 (Scheme 1.66).  
 
Scheme 1.66 Substrate-controlled bromoetherification using glucose-derived 
chiral auxiliary. 
 
The substrate-controlled halolactamization is to some extent as underexploited 
as the haloetherification analogue. Recently it was disclosed by Li’s group that 
an acyclic imide appended with an oxazolidine chiral auxiliary could afford 
cyclic imides in good yields and moderate-to-excellent des in a two-step 
procedure
149
 (Scheme 1.67).  
 
Scheme 1.67 substrate-controlled halolactamization. 
1.2.3 Reagent Controlled Asymmetric Halocyclization 
Reactions 
Although the methods constructing haloheterocycles have been well 
developed and widely used in organic synthesis, the enantioselective version 
of this kind of reactions is rare, especially the catalytic enantioselective 
reactions. Two strategies by means of chiral substrate- and reagent-controlled 
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transformations were investigated so far. While the substrate-controlled 
approach has been shown to be efficient in obtaining good enantioselectivity 
as discussed above, its general application is restricted due to the limited 
availability of chiral precursors. Recent interest is shifted to the reagent-
induced asymmetric halolactonization. 
In 1992, Taguchi and co-workers reported a desymmetrizing enantioselective 
iodolactonization reaction of 2-allyl-2-hydroxy-4-pentenoic acid (214) with 
iodine in the presence of 1 equivalent of a titanium complex generated from 
(Me, Ph)-taddol (213) and Ti(OiPr)4 to afford the corresponding γ-lactone cis-
215 with 65% ee
150
 (Scheme 1.68).  
 
Scheme 1.68 Iodolactonization with chiral titanium taddolate. 
In the research of Gao’s group, metal complex was also used but as catalyst.151 
With the optimized conditions--0.4 equivalent of salen–Co (II) (216) as Lewis 
acid, toluene as solvent, 0.25 equivalent of NCS as additive, and 1.4 
equivalent of I2 as I
+
 source at –18 °C. Seven substrates have been screened, 
and the highest ee value can reach 83% (Table 1.2). 





Grossman and co-workers used dihydroquinidine-halogen complex as chiral 
source of positive halogen ion to conduct the iodolactonization reaction, low 





Scheme 1.69 Iodolactonization with dihydroquinidine-iodine complex. 
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In a study of asymmetric bromolactonization, Brown and co-workers found 
that when chiral halogen source (222) was used, some enantioselectivity can 
be achieved
115
 (Scheme 1.70). 
 
Scheme 1.70 Bromolactonization with bis((-)-2-menthylpyridine)bromonium 
triflate. 
 
After screening kinds of chiral primary amine ligands, Wirth and co-workers 
found that using ICl as the halogen source, together with 2 equivalent of chiral 
amine-- (R)-1, 2, 3, 4-tetrahydronaphthylamine (225), dichloromethane as 
solvent, reacted at -78
o
C, up to 49% ee can be obtained
153,154





















Table 1.3 Iodolactonization with iodine monochloride chiral amine complex. 
 
 
In the study of enantioselective 5-endo halolactonization reactions by 
Rousseau and co-workers,
155
 chiral amines were also used at (more than) 
stoichiometric amount, also only moderate ee was obtained. 
With 1.1 equiv of cinchona alkaloids as chiral ligands (228 or 229), the 
asymmetric iodolactonization of 5-aryl-4-pentenoic acids (230) was 
achieved
156














Table 1.4 Iodolactonization with cinchona alkaloids as chiral sources. 
 
 
While catalytic asymmetric iodolactonization can be achieved when chiral 
quaternary ammonium salts derived from cinchonidine were applied with 
moderate ee value
157















Table 1.5 Iodolactonization catalyzed by chiral quaternary ammonium salts 
derived from cinchonidine. 
 
 
All those trials mentioned above paved the way for the further development of 
enantioselective reactions of this type.  
The first successful halocyclization with ee ≥ 90% was developed by Kang 
and coworkers in 2003
158
. A catalyst system derived from (R,R)-salen-Co(II) 
complex and NCS was used to effect the enantioselective iodocyclization of γ-





Table 1.6 Iodoetherification using a catalyst system derived from (R,R)-salen-
Co(II) complex and NCS 
 
 
Recently, a breakthrough came from the Borhan group,
159
 the catalytic 
enantioselective chlorolactonization of 4-aryl-substituted 4-pentenoic acids 
(241) through the interaction of (DHQD)2PHAL (239, 0.1 eq) with 1,3-
dichloro-5,5-diphenylhydantoin (DCDPH, 240, 1.1 eq) to afford lactones 242 
with high enantioselectivity (up to 90% ee). The associative complex between 
catalyst 239 and DCDPH (240) is thought to be the crucial intermediate 









Table 1.7 Chlorolactonization catalyzed with (DHQD)2PHAL. 
 
 
Another breakthrough was made by Tang and co-workers,
160
 who reported an 
impressive highly enantioselective bromolactonization of 5-en-7-ynyl acids 
(244) and 6-en-8-ynyl acids (246) in the presence of the quinuclidine-based 
urea catalyst (243, 0.2 eq) to afford allenyl bromides 245 and 247 respectively 
with up to 99% ee (Scheme 1.71). Catalyst 243 may serve as a bifunctional 
catalyst to activate the system through deprotonation of the acid and the 
formation of hydrogen bonds with NBS; in these processes, the quinuclidine 
and urea groups are both critical. Owing to the presence of the conjugated C-C 
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triple bond, not only the lactone ring, but also synthetically useful chiral 
allenyl bromide functionality was formed. 
 
Scheme 1.71 Bromolactonization of conjugated (Z)-enynes. 
With aminourea derivative 248 as catalyst, N-iodo-4-fluorophthalimide 249 as 
halogen source, iodine as addictive, toluene as solvent, at -80
o
C, Jacobson and 
co-workers succeeded to conduct the iodolactonization of 4-substituted 4-
pentenoic acids (252) as well as 5-substituted hexenoic acid (250) with up to 
90% and 96% ee respectively
161















Table 1.8 Iodolactonization catalyzed with chiral tertiary aminourea. 
 
 
With the C3-symmetric trisimidazoline 53, DBDMH as halogen source, 
toluene as solvent, at -40
o
C, Fujioka and co-workers managed to do the 
bromolactonization of 5-substituted hexenoic acid with up to 91% ee. And the 
complex of the catalyst and substrate with 1/3 ratio was deemed to play a 
important role
162













And the first asymmetric fluorocyclization was achieved by V. Gouverneur 
and coworkers
163
. Under the following condition: NFSI (1.2 eq), 
(DHQ)2PHAL (0.2 eq), K2CO3 (6 eq), acetone, -78 
o
C, a relatively wide range 
of substrates (260, R
1 
= H, O-alkyl, O-allyl, Ar; R
2
 = H, alkyl, allyl; XH = OH, 
NHTs, NHCOMe, NHCO2Me, NHCO2Bn, NHBoc)can be transformed to 
tetrahydrofuroindole (261) with moderate to excellent ee and yield (Scheme 




Scheme 1.72 The first asymmetric fluorocyclization using (DHQ)2PHAL as 
catalysts and NFSI as fluorine source. 
 
Another asymmetric fluorocyclization was reported by F. Dean Toste and 
coworkers
164
. With the chiral phosphate (262) as catalyst and selectfluor as 
fluorine source the dihydropyran substrates tethered to benzamide (264) would 
be transformed to spiro-fused oxazoline (265) with excellent yield and ee. And 
this methodology can also enable efficient fluorocyclization of 
dihydronaphthalene and chromene substrates that are considered as 
challenging targets due to their less electron-rich properties (Scheme 1.73).   
 
Scheme 1.73 Asymmetric fluorocyclization using chiral phosphate as catalyst. 
Under similar conditions that was used for the asymmetric chlorolactonization 
reaction
159
 disclosed by Borhan’s group, unsaturated amides (266) can be 
converted to oxazolines (267) with excellent ee value
165
. Different substrates 




 both gave satisfying results, and the 
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Scheme 1.74 Cyclization reaction of unsaturated amides with (DHQD)2PHAL 
as catalyst. 
 
After further modifications on the alkaloid-derived thiocarbamate catalysts 
(268), unsaturated sulfonamides (269) can be transformed to pyrrolidines (270) 
with high yield and excellent ee
166
 (Scheme 1.75). 
 





Following the designing concept that by using halogen source which is poorly 
dissolved in nonpolar solvents, the exchange of the anions from halogen 
source with lipophilic chiral phosphate anions brings the active electrophile 
into solution as a chiral ion pair, resulting in efficient, chemo- and 
enantioselective fluorination of the substrate at or near room temperature, F. 
Dean Toste and coworkers successfully expand their chiral phosphate phase 
transfer catalyst to the field of bromocyclizaion and iodocyclization 
reactions
167
.  The enantioenriched 4H-3,1-benzoxazines (274) can be produced 
with good tolerance of both R group and various substituted Ar group 
(Scheme 1.76). 
 
Scheme 1.76 Cyclization reaction of unsaturated amides with chiral phosphate 
phase transfer catalyst. 
 
A new series of thiocarbamate catalysts were developed in our group starting 
from L-proline, producing O-alkyl type catalyst (275) as well as unexpected S-
alkyl type catalyst (276), which were proved to be efficient in the asymmetric 
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bromolactonization of 4-substituted 4-pentenoic acids (277) and 5-substituted 
5-hexenoic acids (279) respectively 
168
 (Scheme 1.77). 
 
Scheme 1.77 Asymmetric bromolactonization using L-proline derived 
thiocarbamate catalysts. 
 
By changing the achiral counterion of the bis(amidine) (BAM) -based protic 
acid complex instead of restructuring the chiral ligand, Jeffrey N. Johnston 
and coworkers developed the chiral stilbenediamine-derived BAM·HNTf2 
catalyst (281) to conduct the iodolactonization reaction with commercial 
available NIS
169




Scheme 1.78 Asymmetric bromolactonization using BAM·HNTf2 type 
catalyst. 
 
Bifunctional partnership of an amidine moiety and a phenolic OH group was 
incorporated into a BINOL template, and the constructed molecule was 
successfully used as catalyst to effect asymmetric bromolactonization reaction 
of 4- and 5-aryl-4-pentenoic acids with 2,4,4,6-tetrabromocyclohexadienone 
(TBCO) as halogen source
170
 (Scheme 1.79). 
 





Through the long history of halogenation reactions, the asymmetric version of 
halocyclization reaction has drawn little attention until recently. After years of 
development, several catalysis systems have been published, yet this area is 
still underexplored in light of catalysis concept as well as substrate scope. 
In the following chapters, the investigation of a new type of selenium catalyst 
















Chapter II: Development of selenium catalysts 
2.1 Hypothesis and Objectives 
Inspired by the studies of the interactions between relatively electron-rich 
chalcogen compounds and halogen compounds pioneered by Zingaro
171-185
 
and the study of Lewis base catalyzed selenolactonization in Denmark’s 
group,
186
 we speculated that the chalcogen-containing compound may be a 
good choice to catalyze halolactonization reaction. 
 




2.2.1 Preliminary investigation on thiocarbamate catalysts 
Following the above mentioned idea, we designed a series of thiocarbamate 
compounds which can be readily constructed by the coupling of corresponding 
isothiocyanates and alcohols. And the thiocarbamates were then subject to the 
bromolactonization reaction of 4-pentenoic acid (292a) and 4-phenylpentenoic 
acid (292b). The competence of thiocarbamate (291a) can be easily 
acknowledged when compared to the analogous carbamate (291c) and the 
existence of the NH is also important for the blockage of which by methyl 
group led to obvious decrease of the reaction rate.  
And we prepared the chiral thiocarbamate (291b) to conduct an attempt of 
asymmetric version of bromolactonization, through no enantioselectivity had 
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be obtained, the catalytic ability was fully approved for near quantitative 
product can be obtained within 5 h, at the temperature of – 78oC (Table 2.1). 
Table 2.1 Thiocarbamate catalyzed bromolactonization. 
 
 
The failure to achieve any enantioselectivity made us to rationalize the 
outcome as followings:  
(1) The chiral moiety linked to the thiocarbamate may be too far away from 
the substrate to induce any enantioselectivity. 
(2) The enantiomerically enriched bromonium-olefin intermediate may suffer 





2.2.2 Development of bifunctional amino-thiocarbamate 
catalysts 
Toward these problems, a possible solution was devised, that is to pull the 
electrophilic bromonium ion and the olefinic substrate into a near proximity. 
We therefore decided to incorporate a Br activator (a thiocarbamate) and a 
carboxylate activator (an amine) into a single molecule, and the resulting 
amino-thiocarbamate bifunctional catalyst was investigated. 
2.2.2.1 Cinchonine derived thiocarbamate catalysts 
We were delight that the above mentioned concept was approved by the 
appreciable enantiomeric excess offered by catalysts 294. Then we chose to 
incorporate the thiocarbamate moiety to the cinchona alkaloids, whose 
derivatives have proven to catalyze an astonishing array of enantioselective 
transformations (Table 2.2). 
And it was surprising to find that the cinchonine derivative 295b can gave 
293b with 37% ee, further modification led to 295e, which can deliver 50% ee. 
A quinidine derived catalyst 296 gave the same ee as 295e, and a conversed ee 
can be obtained with 298 by almost the same value. Other changes, for 
example replacing the phenyl group with bulky alkyl group, or changing the 








Table 2.2 Amino-thiocarbamate-catalyzed bromolactonization. 
 
 
2.2.2.2 Optimization of reaction conditions 
Then different solvents were screened after the catalyst 295e was identified 
(Table 2.3). And the combination of chloroform and toluene with a ½ ratio 
was found to be able to improve the ee to 87%, and higher reaction rate was 
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realized with a higher reaction concentration without any obvious lose of 
enantioselectivity.  




After that, a series of different halogen sources were screened. No reaction 
happened when NCS was used, and much lower ee was obtained when NIS 
was used. So we tried other bromine sources, for example, NBP, and DBDMH, 
none of which can deliver comparable results as NBS.  
Based on our hypothesis that the sulfur species in the catalyst would interact 
with the bromine atom in the halogen reagent, a weak hydrogen bond donor 
would coordinate to the carbonyl group of succinimide and further enhance 
the interaction between Br and sulfur (Table 2.4). And after several rounds of 
screening, NsNH2 (0.5 eq) was found to be capable of improving the ee to 
90%.  
Finally, it was delighted to find that the reaction was readily scalable without 
losing any efficiency and enantioselectivity. 
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Table 2.4 Halogen source and addictive screening on the bromolactonization 
of 292b 
 
2.2.2.3 Substrate scope 
With the optimized conditions, a wide scope of substrates was then screened. 
The reactions were all performed smoothly with high yields and ees in general, 
while much lower ee was obtained when R group equals an electron-rich 













The synthetic utility of this protocol was demonstrated by the preparation of 
301, which is a key intermediate for the synthesis of specific VLA-4 
antagonists 302 (Scheme 2.1). 
 
Scheme 2.1 Asymmetric Synthesis of 301. 
 
2.3 The development of selenium catalysts 
In our preliminary research on Lewis base catalyzed halolactonization 
reactions, triphenylphosphine selenide was found to be able to catalyze the 
reaction even at very low catalytic loading (< 0.1 % equiv). Based on the 
above mentioned studies and the preliminary result of our own research, the 




Scheme 2.2 Proposed mechanism of bromolactonization reaction catalyzed by 
triphenylphosphine selenide. 
 
With the aim to achieve asymmetric catalysis of halocyclization reactions with 
chalcogen-centred catalysts, we decided to incorporate the selenium atom into 
a chiral skeleton.  
 
2.3.1 Cyclic Selenourea Type Catalysts 
So we firstly tried the Se=X type of catalyst as the chiral version of 
triphenylphosphine selenide, the selenourea type catalyst was synthesized 
following the procedure below (Scheme 2.3). 




Firstly, diimine (304) was prepared through condensation reaction of chiral 
amine (303) and glyoxal. After filtration and evaporation, the crude product 
was reduced with sodium borohydride to afford diamine (305). Then 
cyclization reaction was conducted to produce NHC precursor (306), which 
was then deprotonated and reacted with elemental selenium to afford the 
desired product (307). 
But there was one crucial drawback that thwarts the catalytic effect of this 
type of catalyst; it decomposed to the corresponding urea which had no 
catalytic effect during the reaction (Scheme 2.4). And actually no ee was 
obtained when the catalyst was screened using substrate 292b. 
 
Scheme 2.4 The decomposition of selenourea. 
 
2.3.2 Cinchonine Derived Selenocarbamate Catalysts 
Another series of the Se=X type catalyst we have explored was 
selenocarbamate catalyst, which was inspired by the success of the sulfur 
version catalysts in the asymmetric bromolactonization reaction
187
. Eight 




Scheme 2.5 Syntheses of selenocarbamate catalysts. 
 
From various aniline (309), the corresponding isoselenocyanates (311) can be 
prepared in two steps, then the desired catalysts (312) can be obtained through 
a simple coupling reaction between 311 and (+) cinchonine.  






















Table 2.6 Bromolactonization catalyzed with selenocarbamates. 
 
Though moderate ee can be achieved, we did not further explore in this 
direction mainly for reasons listed below: 
1. The purity condition of catalysts prepared was not satisfying, which make it 
hard to elucidate the mechanism even a good ee vale was obtained. 
2. The reaction of last step preparing these catalysts was sometime not 
reproducible, especially when the isoselenocyanate has an electron-donating 
group attached. This is maybe due to the reduced eletrophilicity of the carbon 
atom. 
3. It was found that the catalyst was unstable and decomposed during the 
reaction. In addition, 312 gradually turned reddish brown if it is not stored 
under an inert, anhydrous atmosphere. 
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2.3.3 Cyclic X-Se-X Type Catalysts  
In this case, we moved to another type of selenide catalyst whose structure we 
think would be more stable — the X-Se-X type. 
2.3.3.1 BINOL derived cyclic selenium catalysts 
And we introduced the BINOL scaffold into our catalyst to see if any 
enantioselectivity would be achieved. To our surprise, even the simplest 
structure of this series can induce measurable and reproducible ee value (11%) 
for substrate 292b. 
Scheme 2.6 Synthesis of cyclic binaphthyl selenide. 
 
After the activation of phenol alcohols with Tf2O in (S)-BINOL, 315 can be 
prepared through a Kumada coupling, and 316 was formed through a benzylic 
radical bromination, then the cyclic selenium 317 was obtained through a SN2 
reaction via the in situ generated Na2Se (Scheme 2.6). 
Realizing the capacity of the cyclic chiral selenide, we intended to prepare 
more derivatives which would be likely to induce higher enantioselectivity. 
But after literature searching, it was found that the modification of this type of 
compounds needs too many synthetic steps, which would obviously 
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undermine the efficiency of our research. And the high price of the starting 
material was also a concern. 
 
2.3.3.2 D-Mannitol derived cyclic selenium catalyst 
With the sense that other cyclic selenides may also work, we decided to 
synthesize a series of chiral five-member ring selenide. After the 
retrosynthetic analysis with the consideration of the availability of the starting 
material, we decided to start from the natural product—D-mannitol (Scheme 
2.7). 
 
Scheme 2.7 Retrosynthetic analysis of chiral five-member ring selenide. 
 
Trying to achieve the diversity of structures, the following strategies were 
adapted. 
 
Scheme 2.8 Synthesis of intermediate 322 from D-mannitol. 
 
The key intermediate 3,4-O-isopropylidene-D-mannitol (322) was synthesized 
from D-mannitol in two steps (Scheme 2.8)
188
, followed by modifications to 
afford intermediates 326 and 327
189




Scheme 2.9 Synthesis of intermediate 326 from 322. 
 
 
Scheme 2.10 Synthesis of intermediate 327 from 322. 
 
And further modifications of intermediates 326 and 327 can lead to a variety 
of desired cyclic selenide catalysts (Scheme 2.11 and 2.12). 
 





Scheme 2.12 Modifications of intermediate 327. 
 
The catalytic activities of catalysts 325, 328, and 331 were tested and listed 




















Table 2.7 Bromolactonization catalyzed with cyclic selenium catalysts. 
 
 
Compound 331f was chosen for further study.  
Firstly, the replacement of acetonide group was performed, and the resultant 
diol was protected by other type of protecting groups.  
The acetonide was first remove to afford 332 (Scheme 2.13). 
 
Scheme 2.13 Preparation of intermediate 332. 
 
Then diol was protected by various groups, and the products were screen by 








Table 2.8 Modifications of intermediate 332 and result of the ee test. 
 
 
From the result above, we can see that the bicycle skeleton trans-
bicyclo[3.3.0]octane type structure in our catalysts is critical to the asymmetric 
catalytic effect. So further modifications should maintain the cyclic ketal 
structure. 
2.4 Summary 
In this chapter, cinchonine derived thiocarbamate catalysts were developed, 
and proved to be efficient to catalyze asymmetric bromolactonization reaction.  
The selenium catalysts were then investigated and three generations of 
selenium catalysts have been developed, namely, cyclic selenourea, 
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cinchonine derived selenocarbamate, and cyclic X-Se-X type catalysts, the last 
type among which was proved to be relatively stable and more readily to be 
modified to construct a library. 
Preliminary investigation of the cyclic X-Se-X type catalysts have been 
conducted, mainly using the unsaturated carboxylic acid as substrate. Low ee 
was obtained, indicating that the chiral information can be transferred, while 
not efficiently, so future research would be focused on the screening of new 













Chapter III: Asymmetric bromoaminocyclization reactions 
catalysed by cyclic selenium catalysts 
In the following stage of our research, we chose unsaturated sulfonamide as 
substrate, for the active proton of sulfonamide also shows some extend of 
acidity through much weaker than that of carboxylic acid, it would possibly 




3.1 Asymmetric bromoaminocyclization of disubstituted 
substrates 
With our best cyclic selenium catalyst in the halolactonization reaction, the 
haloaminocyclization reaction was screened (Table 3.1). 




 And it was surprising that the 3-nitro isomer (334b) can give more than 40% 
ee, which was much more than its 2 (334a) and 4-nitro isomers (334c) that 
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gave only 1% and 11% ee respectively. And the analogue with one more 
carbon on the chain (334d) that was supposed to give six-membered ring 
product can not react in the same reaction condition. 
3.1.1 Catalysts screening 
Then we screened all of the cyclic selenium catalysts and the tert-butyl 
substituted one (331k) gave the best enantioselectivity (Table 3.2a and b). 





Table 3.2b Screening of catalysts on the bromoaminocyclization reaction. 
 
  
3.1.2 Screening on other parameters 
With the best catalyst 331k in hand, we screened other parameters, like 
solvent(s), catalyst loading, reactant concentration, and addictive(s).  
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The oxidation of selenium by NCS or NBS in the presence of water is a 
known procedure
192
, and the acetonide may also be removed by trace amount 
of acid derived from the decomposition of NBS in the presence of water 
producing a less potent catalyst. So our first concern was to keep the reaction 
system free of moisture and commonly used drying agents were screened 
(Table 3.3). 
Table 3.3 Screening of drying agents for the bromoaminocyclization reaction. 
 
 
So in the following screening the MgSO4 (100mg) was used as drying agent. 
And the investigation of the loading of catalyst indicated that with higher 
catalyst loading, the enantioselectivity would improved to some extent but not 
significantly, while the product yield would drop significantly, which is barely 
reported in literature. (Table 3.4) 
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The concentration of the reactants was also studied (Table 3.5), and the 
dilution of the reaction leaded to decrease of the enantioselectivity. 
Considering the amount of substrate needed as well as the volume of the 













Some addictives also have been screened, but no obvious improvement was 


























Table 3.6 Screening of addictives for the bromoaminocyclization reaction. 
 
 
The existence of m-nitro group was kind of indispensable considering the 
significantly different ee value compared with those of its 2 and 4-nitro 
isomers, so other analogues was screened, for example, m-acetyl, m-
trifluoromethyl, p-acetamide, but none of them can give parallel result as the 
m-nitro one. When no substituents attached on the benzene ring, almost no ee 












Table 3.7 Screening of other substituents for the bromoaminocyclization 
reaction. 
 
Higher loading of bromine source used would not lead to an improvement of 
the ee value, and other bromine sources were also investigated (Table 3.8), of 
which NBP and DBH both gave better result than NBS, and recrystallized 























With all the above settled parameters: drying agent-MgSO4 (0.1 g), catalyst 
loading-0.2 equivalent, reactant concentration-0.03M, bromine source loading-
1.1 equivalent, and bromine source-NBP, different solvents as well as solvent 










Table 3.9a Screening of solvent for the bromoaminocyclization reaction. 
 
 
All solvents that containing oxygen atom(s) -methanol, ether, THF, EA, and 
acetone- gave poor enantioselectivity, and chloroform can gave higher ee at -
60 
o
C compared to dichloromethane at the same temperature. The combination 
of dichloromethane and toluene gave a higher ee value of 71%. 
Much higher reaction rate can be expected when more dichloromethane was 
used in the combination, but the ee dropped; and when more toluene was used 
both the yield and ee value decreased. When almost equal amount of the two 
solvents was used, the optimum result was obtained-yield as well as ee. Some 
analogues of toluene were also used-benzene, chlorobenzene, m-xylene, and 
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mesitylene, but they cannot give parallel results. When the solvents were 
purged with nitrogen before use, the result was not apparently different, 
indicating that trace amount of air dissolved in the solvent would not affect the 
enantioselectivity (Table 3.9b). 
Table 3.9b Screening of solvent for the bromoaminocyclization reaction. 
 
 
And CaSO4 was found to be a better drying agent by accident, which can push 
the ee up by around 2%. But soon later the result was found to be 
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irreproducible, and we decided to not use any drying agents any more to keep 
the result repeatable (Table 3.10). 
Table 3.10 Clarified result of drying agents effect. 
 
3.2 Substrate modifications 
After all these investigation on different parameters, the ee was still not 
satisfying. And we scrutinized the structure of the substrate, which can be 
divided into three main parts arbitrarily; it was decided to modify the substrate 
part by part (Figure 3.1). 
 
Figure 3.1 Modification of substrate. 
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3.2.1 Modification on the 3-Ns 
Firstly, the modifications were made on the 3-Ns part. 
The substrate can be obtained by simply coupling of primary amine and 
substituted 3-nosylthionyl chloride (Scheme 3.1). 
 
Scheme 3.1 Retrosynthetic analysis of substrate 336. 
And the primary amine was prepared by the following pathway (Scheme 3.2). 
 
Scheme 3.2 Synthesis of primary amine 337. 
 
Different 3-nosylthionyl chloride was prepared by the reaction of 
chlorosulfuric acid and the corresponding nitrobenzene (Scheme 3.3). 
 
Scheme 3.3 Synthesis of 3-nosylthionyl chloride. 
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Thus, different electron withdrawing groups (F, Cl) and electron donating 
groups (Me, MeO) were incorporated into the 3-nosyl part. And the resulting 
substrates were subject to the screening reaction with the condition modified 
previously. 
The result showed that 2-substitued groups led to lower yield and the ee value 
were also inferior compared to the corresponding 4-substitued ones. And the 
trend of different substituents were not very clear actually, for both electron 
withdrawing groups (F, Cl) and electron donating groups (OMe) gave more 
than 70 % ee (Table 3.11).     





3.2.2 Modification on the 4-substituted benzene ring 
Then we tried to incorporate different substituents on the left benzene ring 
(Scheme 3.4).  
 
Scheme 3.4 Retrosynthetic analysis of substrate 346. 
The 3-nosylsulfonamide (348) is commercial available, so the main concern 
was to construct the mesylate (347) (Scheme 3.5). 
 
Scheme 3.5 Synthesis of mesylate 347. 
When R group was a simple alkyl substituent, the enantioselectivity was poor. 
While strong electron withdrawing or donating group on benzene ring led to 
significant drop of ee values; and when R was heteroaromatic group the ee 









Table 3.12 Screening result for the 4-substituent modified substrates. 
 
 
3.2.3 Screening on different type of alkenes 
Then we altered the pattern of the central alkene. The sulphonamide 356 can 
be transformed from different primary alcohols (Scheme 3.6).  
 
Scheme 3.6 Retrosynthetic analysis of substrate 356. 














Scheme 3.7 Synthesis of primary alcohols. 




Figure 3.2 Screening result of different type of unsaturated sulfonamides 
(under same reaction conditions of Table 3.10). 
 
Following the trend, we moved to the development of asymmetric 






3.3 Asymmetric bromoaminocyclization of trisubstituted 
unsaturated sulfonamide 
3.3.1 Optimization of reaction conditions 
Based on the observation of the behaviours of cyclic selenium catalyst under 
different conditions, we briefly screened some parameters, like bromine 
source, solvents, and reaction concentration. And we further modified the 
substituents of the catalysts, finding that bigger substituent can gave higher ee 
value (Table 3.13). 




3.3.2 Substrate scope 
As for the preparation of substrates, the Johnson's version of Claison 
rearrangement was proved to be a good method
193
. Starting from 
atropaldehyde
194
, allyl alcohols can be produced by the reaction with different 
Grignard reagents, then after the rearrangement, the methyl esters can be 
obtained, followed by the route to produce desired products (Scheme 3.8). 
 
Scheme 3.8 The preparation of trisubstituted substrates. 























The brominated five-membered ring system can be then transformed to a 2,3-
disubstitued piperidine skeleton stereospecificly. The tertiary hydroxyl group 
can be dehydrated to construct 3,4-unsaturated piperidine (Scheme 3.9).  
 
Scheme 3.9 The construction of 2,3-disubstituted piperidine from 375d. 
And for the products from which the R
1 
containing a functional group like 
alkene, more modifications can be exerted, for example, the hydroboration can 
give primary alcohol (Scheme 3.10). 
 
Scheme 3.10 The transformation of 382h. 
We speculate that the mechanism of this cyclic-selenium catalyzed bromocyc-
lization reaction may involve the following sequence (Scheme 3.11): (1) 
Coordination of the Lewis basic selenium 331 to NBP would form activated 
electrophilic brominating species A. (2) Subsequent interaction between A and 
the olefinic substrate would then give a tight selenium coordinated bromonium 
intermediate species, B. We suspect that the tight pair may help mitigate the 
halogen degeneration and racemization (without the use of a bifunctional 
pocket that could encapsulate the halonium intermediate), which may explain 
the high enantioselectivity. (3) Se−Br−olefin intermediate B would then 
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undergo SN2 attack by the sulfonamide to give the desired product with 
regeneration of catalyst 331. The dominant role of the bromonium 
intermediate B would explain the excellent regioselectivity (Markonikov type) 
and stereoselectivity (anti relationship of Br and Ns). 
 




In summary, we have developed the first Lewis basic selenium catalyzed 
asymmetric bromocyclization of tri-substituted olefinic amide. The 
enantioenriched pyrrolidine products, which contain two stereogeneric centres, 
could undergo rearrangement to yield the corresponding 2,3-disubstituted 
piperidine in excellent diastereo- and enantioselectivity. 
Though up to 95% ee can be obtained as well as good yield, for some 
substrates both ee and yield are not satisfying, so future work will be focus on 
the elucidation of the mechanism for this catalysis system with the possibility 





Chapter IV: Experimental 
4.1 General Information 
All reactions that required anhydrous conditions were carried out under 
nitrogen atmosphere. Commercially available reagents were used as received 
from Alfa Aesar, Sigma-Aldrich and TCI-Tokyo Kasei Kogyo Co. Ltd. THF, 
dichloromethane, diethyl ether, and toluene were dried with solvent 
purification system of PURE SOLV, innovative technology; ethanol was dried 
by distillation over the appropriate drying reagents. HPLC grade chloroform 
was purchased from Fischer Chemicals while HPLC grade hexane and 
isopropanol were purchased from Tedia and used as received. Analytical thin 
layer chromatography (TLC) was performed with Merck pre-coated TLC 
plates, silica gel 60 F-254, layer thickness 0.25 mm. The plate were visualized 
under 254 nm UV light and stained with potassium permanganate or 
ammonium molybdate. Flash chromatography separations were performed on 
Merck 60 (0.040-0.0063 mm) mesh silica gel. 
1
H NMR and 
13
C NMR spectra 
were recorded on a Bruker ACF 300 (300MHz) and AMX500 (500 MHz) 
spectrometer. Chemical shift (δ) are reported in parts per million (ppm) 
relative to tetramethylsilane (TMS, δ=0.00) for 1H NMR and are referenced to 
the residual solvent peak chloroform (δ=7.26) or dichloromethane (δ=5.31). 
Chemical shift for 
13
C NMR are reported in ppm downfield from TMS and are 
referenced to the carbon resonance of the solvent chloroform (δ=77.0) or 
dichloromethane (δ=53.73). Data are represented as follow: chemical shift, 
multiplicity (br. s = broad singlet, s = singlet, d = doublet, t = triplet, q = 
quartet, quin = quintet, sex = sextet, sep = septet, m = multiplet), coupling 
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constants in Hertz (Hz). Low resolution mass spectra (ESI) were obtained on a 
Finnnigan/MAT LCQ spectrometer. High resolution mass spectra (ESI) were 
obtained on Finnnigan/MAT 95XL-T spectrometer. Enantiomeric excesses 
were determined by HPLC analysis on Shimadzu HPLC units, including the 
following instruments: LC-20AD pump, SPD-20A detector and Dacicel 
Chiralpak IA, IB, IC, ID, IE or ODH columns. Optical rotations were recorded 
on a Jasco DIP-1000 polarimeter. Infrared spectra were recorded on a Varian 
3100 FTIR spectrophotometer and reported in wave numbers (cm
-1
). Melting 
points were determined on a BÜCHI B-540b melting point apparatus. 
 
4.2 Preparation of cyclic selenium catalysts 331 
 
General Procedure for the preparation of cyclic selenium catalyst 
To a solution of the diol 329 (4.0 mmol, 1.0 eq) and Et3N (1.7 mL, 12.0 mmol, 
3.0 eq) in CH2Cl2 (30 mL) was added MsCl (0.8 mL, 10.0 mmol, 2.5 eq) 
dropwise over 10 min at 0°C and the reaction mixture was stirred at 25 °C for 
12 h. The reaction solution was then diluted with CH2Cl2 (20 mL), washed 
with water (50 mL), and extracted with CH2Cl2 (20 mL × 3).  The combined 
organic layer was dried over sodium sulfate, filtered, and concentrated in 
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vacuo. The resulting crude mesylate 330 was used in next step without further 
purification. 
To a mixture of selenium powder (1.28 g, 16.0 mmol, 4.0 eq) and sodium 
borohydride (0.76 g, 20.0 mmol, 5.0 eq) was added ethanol (50 mL) slowly in 
such a way to maintain a gentle gas evolution at 0 °C. After 0.5 h, a solution 
of mesylate 6 (4.0mmol, 1.0eq) in THF (20 mL) was added dropwise over 10 
min. The resultant solution was heated to reflux for three days. Then the 
reaction was cooled to 25 
o
C, water (100 mL) was then added and the aqueous 
layer was extracted with CH2Cl2 (60 mL × 3). The organic layer was dried 
over sodium sulfate, filtered, and concentrated in vacuo. The residue was 




Light yellow oil; [] 25D  -129.3 (c 2.1, CHCl3); IR (KBr): 2971, 1598, 1499, 




H NMR (300 MHz, CDCl3): δ 7.35-7.28 (m, 4H), 7.02-
6.93 (m, 6H), 4.69 (dd, J = 4.5, 2.1 Hz, 2H), 4.57 (dd, J = 10.1, 5.2 Hz, 2H), 
4.21 (dd, J = 10.1, 8.1 Hz, 2H), 3.87-3.80 (m, 2H), 1.51 (s, 6H); 
13
C NMR (75 
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MHz, CDCl3):  158.5, 129.4, 121.2, 119.4, 114.9, 82.7, 68.4, 33.0, 27.2; 
HRMS (EI) calcd for C21H24O4Se m/z [M]
+




Light yellow solid; mp 111.5–113.4 °C; [] 25D  -256.0 (c 1.7, CHCl3); IR (KBr): 




H NMR (500 MHz, CDCl3): δ 7.10 
(d, J = 8.5 Hz, 4H), 6.85 (d, J = 8.5 Hz, 4H), 4.67 (dd, J = 4.5, 2.0 Hz, 2H), 
4.53 (dd, J = 10.1, 5.2 Hz, 2H), 4.17 (dd, J = 10.0, 8.2 Hz, 2H), 3.83-3.79 (m, 
2H), 2.31 (s, 6H), 1.50 (s, 6H); 
13
C NMR (125 MHz, CDCl3):  156.4, 130.4, 
129.8, 119.3, 114.8, 82.7, 68.7, 33.0, 27.2, 20.5; HRMS (EI) calcd for 
C23H28O4Se m/z [M]
+






Light yellow oil; [] 25D  -296.4 (c 2.0, CHCl3); IR (KBr): 2984, 1594, 1458, 




H NMR (500 MHz, CDCl3): δ 6.72 (s, 2H), 6.69 (s, 
4H), 4.75 (dd, J = 4.4, 1.8 Hz, 2H), 4.61 (dd, J = 10.0, 5.1 Hz, 2H), 4.25 (dd, 
J = 10.0, 8.1 Hz, 2H), 3.91-3.87 (m, 2H), 2.41 (s, 12H), 1.61 (s, 6H); 
13
C 
NMR (125 MHz, CDCl3):  158.4, 138.9, 122.7, 119.0, 112.5, 82.5, 68.1, 32.9, 
27.1, 21.2; HRMS (EI) calcd for C25H32O4Se m/z [M]
+





White solid; mp 126.1–127.5 °C; [] 25D  -298.5 (c 1.8, CHCl3); IR (KBr): 2962, 




H NMR (500 MHz, CDCl3): δ 7.31 (d, J 
= 8.8 Hz, 4H), 6.88 (d, J = 8.7 Hz, 4H), 4.67 (dd, J = 4.4, 1.9 Hz, 2H), 4.55 
(dd, J = 10.1, 5.1 Hz, 2H), 4.17 (dd, J = 9.9, 8.2 Hz, 2H), 3.83-3.79 (m, 2H), 
1.50 (s, 6H), 1.31 (s, 18H); 
13
C NMR (125 MHz, CDCl3):  156.3, 143.9, 
126.2, 119.4, 114.5, 82.8, 68.7, 34.1, 33.1, 31.5, 27.3; HRMS (ESI) calcd for 
C29H40NaO4Se m/z [M + Na]
+






Light yellow solid; mp 81.2–82.7 °C; [] 25D  -295.2 (c 1.3, CHCl3); IR (KBr): 




H NMR (500 MHz, CDCl3): δ 7.19 
(d, J = 8.6 Hz, 4H), 6.92 (d, J = 8.6 Hz, 4H), 4.70 (dd, J = 4.4, 1.9 Hz, 2H), 
4.58 (dd, J = 10.1, 5.1 Hz, 2H), 4.20 (dd, J = 9.9, 8.3 Hz, 2H), 3.86-3.82 (m, 
2H), 2.91 (sep, J = 6.9 Hz, 2H), 1.53 (s, 6H), 1.27 (d, J = 7.0 Hz, 12H); 
13
C 
NMR (125 MHz, CDCl3):  156.6, 141.5, 127.2, 119.3, 114.8, 82.7, 68.6, 33.2, 
33.0, 27.2, 24.1; HRMS (EI) calcd for C27H36O4Se m/z [M]
+







Light yellow solid; mp 59.9–61.3 °C; [] 25D  -272.7 (c 1.5, CHCl3); IR (KBr): 




H NMR (500 MHz, CDCl3): δ 7.24 
(d, J = 8.7 Hz, 4H), 6.87 (d, J = 8.7 Hz, 4H), 4.67 (dd, J = 4.4, 1.9 Hz, 2H), 
4.54 (dd, J = 10.1, 5.2 Hz, 2H), 4.17 (dd, J = 9.9, 8.3 Hz, 2H), 3.82-3.79 (m, 
2H), 1.61 (q, J = 7.5 Hz, 4H), 1.49 (s, 6H), 1.26 (s, 12H), 0.67 (t, J = 7.5 Hz, 
6H); 
13
C NMR (125 MHz, CDCl3):  156.2, 142.1, 126.9, 119.4, 114.3, 82.7, 
68.6, 37.3, 36.9, 33.0, 28.6 (two peaks), 27.3, 9.1; HRMS (ESI) calcd for 
C31H44NaO4Se m/z [M + Na]
+
: 583.2299; found: 583.2308; 
 
4.3 Preparation of substrate 356d and 381 
 
General Procedure for the preparation of cis-olefinic amide: To a 
suspension of magnesium turnings (0.4 g, 14.0 mmol, 3.5 eq) and one crystal 
of iodine in THF (15 mL) was added halide R
1
X (10.0 mmol, 2.5 eq) dropwise 
in such a way to maintain a gentle reflux. The resultant solution was stirred at 
25 
o
C for 1 h and cooled down to 0 
o
C. Then a solution of acrylaldehyde 376 
(4.0 mmol, 1.0 eq) in THF (2 mL) was added dropwise over 15 minutes
194,195
. 
The mixture was raised to 25 
o
C and stirred for additional 12 h. The reaction 
was quenched by saturated aqueous NH4Cl solution (20 mL) and extracted 
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with EtOAc (10 mL × 3). The organic layers were dried over sodium sulfate, 
filtered and concentrated in vacuo. The residue was subjected to flash 
chromatography to afford the desired allyl alcohol 377. 
A mixture of allyl alcohol 377 (4.0 mmol, 1.0 eq), propionic acid (30 µL, 0.1 
eq), and trimethyl orthoacetate (8.0 mL, 60.0 mmol, 15.0 eq) was refluxed for 
40 h. The solution was then concentrated in vacuo. The residue was subjected 
to flash chromatography to afford the desired methyl ester product 378. 
To a suspension of LiAlH4 (70 mg, 1.8 mmol, 1.5 eq) in THF (6 mL) was 
added a solution of ester 378 (1.2 mmol, 1.0 eq) in THF (2 mL) dropwise over 
10 minutes at 25 
o
C. The resultant mixture was stirred for additional 3 h. After 
TLC revealed the absence of the starting material, the reaction was quenched 
with deionized water (0.1 mL) and aqueous NaOH solution (1 M, 0.4 mL). 
The mixture was stirred for additional 2 h and filtered. The filtrate was 
concentrated in vacuo and the crude alcohol product 379 was used directly in 
the next step without further purification. 
To a solution of alcohol 379 (1.2 mmol, 1.0 eq) and Et3N (0.35 mL, 2.5 mmol, 
2.0 eq) in CH2Cl2 (8 mL) was added MsCl (0.12 mL, 1.5 mmol, 1.2 eq) at 0 
o
C. 
The resultant mixture was stirred at 0 
o
C for 10 minutes, and was then warmed 
to 25 
o
C and stirred for additional 2 h. After TLC revealed the absence of the 
starting material, the reaction was quenched with water (20 mL) and extracted 
with CH2Cl2 (10 mL × 3). The combined organic extracts were dried over 
sodium sulfate, filtered and concentrated in vacuo. The residue was subjected 




A solution of 3-NsNH2 (0.36 g, 1.8 mmol, 1.5 eq) and KOH (0.1 g, 1.8 mmol, 
1.5 eq) in DMSO (10 mL) was stirred at 110 
o
C for 0.5 h. Then a solution of 
compound 380 (1.2 mmol, 1.0 eq) in DMSO (3 mL) was added dropwise over 
3 minutes at the same temperature. After stirring at 110 
o
C for 1 h, the solution 
was cooled to 25 
o
C. The reaction mixture was diluted with water (10 mL) and 
extracted with Et2O (10 mL × 3). The combined organic extracts were washed 
with brine (20 mL), dried over sodium sulfate, filtered and concentrated in 
vacuo. The residue was subjected to flash column chromatography to give the 
desired product 381. 
 
(Z)-3-nitro-N-(4-phenylhex-4-en-1-yl)benzenesulfonamide (356d)  
Light yellow solid; (major: minor 11:1); mp 84.3–85.8 °C; IR (KBr): 3280, 




H NMR (500 MHz, CDCl3): δ 8.65 
(t, J = 1.9 Hz, 1H), 8.40 (d, J = 8.2 Hz, 1H), 8.14 (d, J = 8.0 Hz, 1H), 7.70 (t, 
J = 8.0 Hz, 1H), 7.30-7.04 (m, 5H ), 5.50 (q, J = 6.8 Hz, 1H), 4.93 (t, J = 5.8 
Hz, 1H), 2.97 (q, J = 7.0 Hz, 2H), 2.33 (t, J = 7.3 Hz, 2H), 1.51 (d, J = 6.8 Hz, 
3H), 1.45 (quin, J = 7.5 Hz, 2H); 
13
C NMR (125 MHz, CDCl3): δ 148.2, 142.4, 
139.9, 139.8, 132.5, 130.4, 128.3, 128.1, 127.0, 126.6, 122.5, 122.1, 42.8, 35.8, 
27.9, 14.5. HRMS (ESI) calcd for C18H19N2O4S [M – H]
–





(Z)-3-nitro-N-(4-phenylhept-4-en-1-yl)benzenesulfonamide (381a)  





H NMR (500 MHz, CDCl3): δ 8.66 (t, J = 1.9 Hz, 1H), 8.41 
(d, J = 8.2, Hz, 1H), 8.13 (d, J = 7.7 Hz, 1H), 7.70 (t, J = 8.0 Hz, 1H), 7.30-
7.03 (m, 5H ), 5.40 (t, J = 7.4 Hz, 1H), 4.72 (t, J = 5.7 Hz, 1H), 2.99 (q, J = 
6.5 Hz, 2H), 2.33 (t, J = 7.3 Hz, 2H), 1.90 (quin, J = 7.4 Hz, 2H), 1.46 (quin, 
J = 7.5 Hz, 2H), 0.88 (t, J = 7.5 Hz, 3H); 
13
C NMR (125 MHz, CDCl3): δ 
148.3, 142.5, 140.2, 138.4, 132.5, 130.5, 130.4, 128.2, 128.1, 127.0, 126.7, 
122.2, 42.8, 35.9, 28.0, 22.2, 14.5. HRMS (ESI) calcd for C19H21N2O4S [M – 
H]
–
: 373.1228; found: 373.1238. 
 
(Z)-3-nitro-N-(4-phenyloct-4-en-1-yl)benzenesulfonamide (381b)  





H NMR (500 MHz, CDCl3): δ 8.66 (t, J = 1.9 Hz, 1H), 8.41 
(ddd, J = 8.2, 2.2, 0.9 Hz, 1H), 8.13 (dt, J = 8.0, 1.0 Hz, 1H), 7.70 (t, J = 8.0 
Hz, 1H), 7.30-7.02 (m, 5H ), 5.40 (t, J = 7.3 Hz, 1H), 4.68 (t, J = 5.7 Hz, 1H), 
2.99 (q, J = 6.5 Hz, 2H), 2.33 (t, J = 7.3 Hz, 2H), 1.86 (q, J = 7.4 Hz, 2H), 





C NMR (125 MHz, CDCl3): δ 148.3, 142.5, 140.3, 139.0, 132.5, 130.4, 
128.8, 128.3, 128.1, 127.0, 126.6, 122.2, 42.8, 36.0, 30.8, 28.0, 23.1, 13.7. 
HRMS (ESI) calcd for C20H23N2O4S [M – H]
–
: 387.1384; found: 387.1399. 
 
(Z)-3-nitro-N-(4-phenylnon-4-en-1-yl)benzenesulfonamide (381c)  





H NMR (500 MHz, CDCl3): δ 8.66 (t, J = 1.9 Hz, 1H), 8.41 
(ddd, J = 8.2, 2.2, 1.0 Hz, 1H), 8.13 (ddd, J = 7.8, 1.7, 1.1 Hz, 1H), 7.70 (t, J 
= 8.0 Hz, 1H), 7.30-7.03 (m, 5H ), 5.40 (t, J = 7.4 Hz, 1H), 4.70 (t, J = 5.7 Hz, 
1H), 2.98 (q, J = 7.0 Hz, 2H), 2.33 (t, J = 7.3 Hz, 2H), 1.88 (q, J = 7.3 Hz, 
2H), 1.46 (quin, J = 7.5 Hz, 2H), 1.29-1.17 (m, 4H), 0.80 (t, J = 7.1 Hz, 3H); 
13
C NMR (75 MHz, CDCl3): δ 148.3, 142.5, 140.3, 138.9, 132.5, 130.4, 128.9, 
128.3, 128.1, 127.0, 126.6, 122.2, 42.8, 36.0, 32.1, 28.5, 28.0, 22.2, 13.9. 
HRMS (ESI) calcd for C21H25N2O4S [M – H]
–
: 401.1541; found: 401.1560. 
 
(Z)-N-(7-methyl-4-phenyloct-4-en-1-yl)-3-nitrobenzenesulfonamide (381d) 





H NMR (500 MHz, CDCl3): δ 8.66 (t, J = 1.8 Hz, 1H), 8.41 
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(d, J = 8.1 Hz, 1H), 8.14 (d, J = 7.8 Hz, 1H), 7.70 (t, J = 8.0 Hz, 1H), 7.30-
7.01 (m, 5H ), 5.42 (t, J = 7.4 Hz, 1H), 4.75 (t, J = 5.8 Hz,1H), 2.99 (q, J = 
7.0 Hz, 2H), 2.34 (t, J = 7.3 Hz, 2H), 1.77 (t, J = 7.1 Hz, 2H), 1.57-1.43 (m, 
3H), 0.79 (d, J = 6.7 Hz, 6H); 
13
C NMR (125 MHz, CDCl3): δ 148.3, 142.5, 
140.4, 139.6, 132.5, 130.4, 128.3, 128.1, 127.7, 127.0, 126.6, 122.2, 42.8, 37.7, 
36.2, 28.8, 28.0, 22.3. HRMS (ESI) calcd for C21H25N2O4S [M – H]
–
: 
401.1541; found: 401.1558. 
 
(Z)-N-(4,6-diphenylhex-4-en-1-yl)-3-nitrobenzenesulfonamide (381e) 





NMR (500 MHz, CDCl3): δ 8.65 (t, J = 1.8 Hz, 1H), 8.38 (d, J = 7.9, 1H), 
8.10 (d, J = 7.9 Hz, 1H), 7.66 (t, J = 8.0 Hz, 1H), 7.34-7.08 (m, 10H ), 5.59 (t, 
J = 7.5 Hz, 1H), 4.69 (br. s, 1H), 3.25 (d, J = 7.5 Hz, 2H), 3.00 (q, J = 6.5 Hz, 
2H), 2.39 (t, J = 7.4 Hz, 2H), 1.50 (quin, J = 7.5 Hz, 2H); 
13
C NMR (125 
MHz, CDCl3): δ 148.3, 142.5, 141.0, 140.3, 139.9, 132.4, 130.4, 128.4, 128.3 
(two peaks), 128.20, 127.0 (two peaks), 126.7, 125.9, 122.2, 42.9, 36.1, 35.0, 
28.0. HRMS (ESI) calcd for C24H23N2O4S [M – H]
–






Light brown oil; (major: minor 8:1); IR (KBr): 3299, 1605, 1532, 1352, 1168, 




H NMR (500 MHz, CDCl3): δ 8.66 (t, J = 1.6 Hz, 1H), 8.40 
(d, J = 8.1, 1H), 8.13 (d, J = 7.8 Hz, 1H), 7.69 (t, J = 8.0 Hz, 1H), 7.29-7.14 
(m, 6H ), 7.07 (d, J = 7.3 Hz, 2H), 6.92 (d, J = 7.1 Hz, 2H), 5.44 (t, J = 7.3 
Hz, 1H), 4.63 (t, J = 5.8 Hz, 1H), 2.96 (q, J = 6.7 Hz, 2H), 2.60 (t, J = 7.6 Hz, 
2H), 2.32 (t, J = 7.3 Hz, 2H), 2.21 (q, J = 7.5 Hz, 2H), 1.43 (quin, J = 7.2 Hz, 
2H); 
13
C NMR (125 MHz, CDCl3): δ 148.3, 142.5, 141.7, 140.1, 139.9, 132.5, 
130.4, 128.5, 128.2 (two peaks), 128.1, 127.6, 127.0, 126.8, 125.8, 122.2, 42.8, 
36.1, 36.0, 30.6, 28.0. HRMS (ESI) calcd for C25H25N2O4S [M – H]
–
: 
449.1541; found: 449.1548. 
 
(Z)-3-nitro-N-(4-phenylocta-4,7-dien-1-yl)benzenesulfonamide (381g)  





H NMR (500 MHz, CDCl3): δ 8.65 (t, J = 1.9 Hz, 1H), 8.41 
(d, J = 8.1 Hz, 1H), 8.13 (d, J = 8.0 Hz, 1H), 7.70 (t, J = 8.0 Hz, 1H), 7.31-
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7.04 (m, 5H ), 5.79-5.71 (m, 1H ), 5.43 (t, J = 7.5 Hz, 1H), 4.96 (dq, , J = 13.5, 
1.7 Hz, 2H ), 4.61 (t, J = 5.9 Hz, 1H), 2.99 (q, J = 6.7 Hz, 2H), 2.64 (t, J = 6.7 
Hz, 2H), 2.37 (t, J = 7.3 Hz, 2H), 1.48 (quin, J = 7.5 Hz, 2H); 
13
C NMR (125 
MHz, CDCl3): δ 148.3, 142.5, 140.4, 139.8, 137.1, 132.5, 130.4, 128.2, 128.1, 
127.0, 126.9, 125.5, 122.2, 114.7, 42.8, 36.0, 33.1, 28.0. HRMS (ESI) calcd 
for C20H21N2O4S [M – H]
–
: 385.1228; found: 385.1228. 
 
(Z)-3-nitro-N-(4-phenylnona-4,8-dien-1-yl)benzenesulfonamide (381h) 





H NMR (500 MHz, CDCl3): δ 8.65 (t, J = 1.9 Hz, 1H), 8.41 
(d, J = 8.2 Hz, 1H), 8.13 (d, J = 8.2 Hz, 1H), 7.70 (t, J = 8.1 Hz, 1H), 7.31-
7.03 (m, 5H ), 5.71 (ddt, J = 16.7, 10.3, 6.3 Hz, 1H), 5.41 (t, J = 6.8 Hz, 1H), 
4.96-4.90 (m, 2H ), 4.60 (br. s, 1H), 2.99 (q, J = 6.7 Hz, 2H), 2.34 (t, J = 7.3 
Hz, 2H), 2.06-1.97 (m, 4H), 1.46 (quin, J = 7.5 Hz, 2H); 
13
C NMR (125 MHz, 
CDCl3): δ 148.3, 142.5, 140.2, 139.5, 138.1, 132.5, 130.4, 128.2 (two peaks), 
127.9, 127.0, 126.8, 122.2, 114.7, 42.8, 36.0, 34.0, 28.1, 28.0. HRMS (ESI) 
calcd for C21H23N2O4S [M – H]
–










H NMR (500 MHz, CDCl3): δ 8.68 (t, J = 1.8 Hz, 1H), 8.39 
(d, J = 8.2 Hz, 1H), 8.16 (t, J = 7.9 Hz, 1H), 7.69 (t, J = 8.0 Hz, 1H), 7.39-
6.87 (m, 10H ), 6.42 (s, 1H), 4.98 (t, J = 6.0 Hz, 1H), 3.05 (q, J = 7.0 Hz, 2H), 
2.51 (t, J = 7.4 Hz, 2H), 1.57 (quin, J = 7.1 Hz, 2H); 
13
C NMR (125 MHz, 
CDCl3): δ 148.2, 142.3, 141.0, 140.2, 136.8, 132.5, 130.5, 128.9, 128.6, 128.4, 
127.8, 127.3, 127.1, 127.0, 126.4, 122.1, 42.7, 37.2, 27.8. HRMS (ESI) calcd 
for C23H21N2O4S [M – H]
–
: 421.1228; found: 421.1239. 
 
(Z)-N-(4-(4-chlorophenyl)hex-4-en-1-yl)-3-nitrobenzenesulfonamide (381j) 





H NMR (500 MHz, CDCl3): δ 8.66 (t, J = 1.9 Hz, 1H), 8.41 
(ddd, J = 8.2, 2.2, 1.0 Hz, 1H), 8.13 (ddd, J = 7.8, 1.6, 1.1 Hz, 1H), 7.71 (t, J 
= 8.0 Hz, 1H), 7.27 (d, J = 8.6 Hz, 2H), 6.99 (d, J = 8.4 Hz, 2H), 5.52 (q, J = 
6.9 Hz, 1H), 4.76 (t, J = 5.6 Hz, 1H), 2.97 (q, J = 6.8 Hz, 2H), 2.32 (t, J = 7.4 
Hz, 2H), 1.51 (d, J = 6.9 Hz, 3H) 1.44 (quin, J = 7.5 Hz, 2H); 
13
C NMR (125 
MHz, CDCl3): δ 148.3, 142.4, 138.7, 138.4, 132.4 (two peaks), 130.5, 129.7, 
128.4, 127.0, 123.3, 122.2, 42.7, 35.7, 28.0, 14.6. HRMS (ESI) calcd for 
C18H18ClN2O4S [M – H]
–










H NMR (500 MHz, CDCl3): δ 8.66 (t, J = 2.0 Hz, 1H), 8.42 
(dd, J = 8.1, 1.6 Hz, 1H), 8.14 (d, J = 7.6 Hz, 1H), 7.72 (t, J = 8.0 Hz, 1H), 
7.30-6.94 (m, 4H), 5.53 (q, J = 6.9 Hz, 1H), 4.72 (t, J = 5.7 Hz, 1H), 2.98 (q, 
J = 6.5 Hz, 2H), 2.31 (t, J = 7.4 Hz, 2H), 1.52 (d, J = 6.8 Hz, 3H), 1.45 (quin, 
J = 7.5 Hz, 2H); 
13
C NMR (125 MHz, CDCl3): δ 148.3, 142.4, 141.9, 138.6, 
134.0, 132.5, 130.5, 129.5, 128.3, 127.1, 126.8, 126.6, 123.6, 122.2, 42.8, 35.7, 
28.0, 14.6. HRMS (ESI) calcd for C18H18ClN2O4S [M – H]
–




Light yellow solid; (major: minor 9:1); mp 84.0–84.9 °C; IR (KBr): 3295, 




H NMR (500 MHz, CDCl3): δ 8.66 
(s, 1H), 8.40 (d, J = 7.4 Hz, 1H), 8.15 (d, J = 8.1 Hz, 1H), 7.71 (t, J = 7.9 Hz, 
1H), 7.03-6.90 (m, 4H ), 5.49 (q, J = 6.5 Hz, 1H), 5.07 (br. s, 1H), 2.96 (q, J = 
6.8 Hz, 2H), 2.31 (t, J = 7.1 Hz, 2H), 1.51-1.42 (m, 5H); 
13
C NMR (125 MHz, 
CDCl3): δ 161.5 (d, J = 245.7 Hz), 148.3, 142.4, 138.8, 135.8, 132.5, 130.5, 
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129.9 (d, J = 7.8 Hz), 127.0, 123.0, 122.2, 115.0 (d, J = 21.1 Hz), 42.8, 35.9, 
27.9, 14.6. HRMS (ESI) calcd for C18H18FN2O4S [M – H]
–










H NMR (500 MHz, CDCl3): δ 8.67 (s, 1H), 8.41 (d, J = 8.0 
Hz, 1H), 8.14 (d, J = 7.6 Hz, 1H), 7.71 (t, J = 8.0 Hz, 1H), 7.57 (d, J = 7.9 Hz, 
2H), 7.19 (d, J = 8.0 Hz, 2H), 5.59 (q, J = 7.1 Hz, 1H), 4.65 (br. s, 1H), 2.99 
(q, J = 7.2 Hz, 2H), 2.36 (t, J = 7.2 Hz, 2H), 1.53-1.44 (m, 5H); 
13
C NMR 
(125 MHz, CDCl3): δ 148.3, 144.0, 142.3, 138.7, 132.4, 130.5, 128.8 (q, J = 
32.4 Hz), 128.7, 127.0, 125.1 (q, J = 3.8 Hz), 124.2 (q, J = 272.1 Hz), 123.8, 
122.1, 42.7, 35.6, 27.9, 14.5. HRMS (ESI) calcd for C19H18F3N2O4S [M – H]
–
: 
427.0945; found: 427.0949. 
 
(Z)-3-nitro-N-(4-(o-tolyl)hex-4-en-1-yl)benzenesulfonamide (381n) 





H NMR (500 MHz, CDCl3): δ 8.66 (t, J = 1.8 Hz, 1H), 8.41 
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(d, J = 8.1 Hz, 1H), 8.13 (d, J = 8.1 Hz, 1H), 7.70 (t, J = 8.0 Hz, 1H), 7.20-
6.83 (m, 4H), 5.48 (q, J = 6.8 Hz, 1H), 4.72 (t, J = 5.6 Hz, 1H), 2.98 (q, J = 
6.8 Hz, 2H), 2.34-2.31 (m, 5H), 1.52 (d, J = 6.8 Hz, 3H) 1.46 (quin, J = 7.3 
Hz, 2H); 
13
C NMR (125 MHz, CDCl3): δ 148.3, 142.5, 139.9 (two peaks), 
137.7, 132.5, 130.4, 128.9, 128.0, 127.4, 127.0, 125.4, 122.4, 122.2, 42.8, 35.9, 











H NMR (500 MHz, CDCl3): δ 8.67 (t, J = 1.9 Hz, 1H), 8.41 
(d, J = 8.2 Hz, 1H), 8.15 (d, J = 7.8 Hz, 1H), 7.71 (t, J = 8.0 Hz, 1H), 7.17-
6.85 (m, 4H), 5.51 (q, J = 6.6 Hz, 1H), 4.47 (t, J = 5.9 Hz, 1H), 3.05-2.98 (m, 
2H), 2.25-2.20 (m, 2H), 2.12 (s, 3H), 1.53-1.44 (m, 2H), 1.33 (d, J = 6.7 Hz, 
3H); 
13
C NMR (125 MHz, CDCl3): δ 148.3, 142.4, 139.8, 139.4, 135.4, 132.5, 
130.4, 129.9, 128.6, 127.0, 126.7, 125.5, 122.7, 122.2, 43.1, 35.7, 27.9, 19.1, 
14.4. HRMS (ESI) calcd for C19H21N2O4S [M – H]
–











H NMR (500 MHz, CDCl3): δ 8.66 (t, J = 1.9 Hz, 1H), 8.41 
(d, J = 8.2 Hz, 1H), 8.13 (d, J = 7.8 Hz, 1H), 7.70 (t, J = 8.0 Hz, 1H), 7.12 (d, 
J = 8.1 Hz, 2H), 6.95 (d, J = 7.9 Hz, 2H), 5.48 (q, J = 6.8 Hz, 1H), 4.46 (t, J 
= 5.8 Hz, 1H), 2.97 (q, J = 6.8 Hz, 2H), 2.34-2.31 (m, 5H), 1.53 (d, J = 6.8 
Hz, 3H), 1.45 (quin, J = 7.3 Hz, 2H); 
13
C NMR (125 MHz, CDCl3): δ 148.3, 
142.5, 139.6, 136.8, 136.3, 132.5, 130.4, 128.8, 128.2, 126.9, 122.3, 122.2, 
42.8, 35.9, 27.9, 21.1, 14.6. HRMS (ESI) calcd for C19H21N2O4S [M – H]
–
: 




Light yellow solid; (major: minor 14:1); mp 88.7–89.7 °C; IR (KBr): 3310, 




H NMR (500 MHz, CDCl3): δ 8.65 
(t, J = 1.8 Hz, 1H), 8.40 (d, J = 8.2, Hz, 1H), 8.13 (d, J = 7.9 Hz, 1H), 7.70 (t, 
J = 8.1 Hz, 1H), 6.97 (d, J = 8.5 Hz, 2H), 6.82 (d, J = 8.6 Hz, 2H), 5.45 (q, J 
= 6.8 Hz, 1H), 4.88 (t, J = 5.6 Hz, 1H), 3.80 (s, 3H), 2.96 (q, J = 6.8 Hz, 2H), 
2.31 (t, J = 7.3 Hz, 2H), 1.52 (d, J = 6.8 Hz, 3H), 1.44 (quin, J = 7.2 Hz, 2H),; 
13
C NMR (125 MHz, CDCl3): δ 158.2, 148.2, 142.4, 139.2, 132.5, 132.0, 
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130.4, 129.4, 126.9, 122.2, 122.1, 113.5, 55.2, 42.8, 35.9, 27.9, 14.6. HRMS 
(ESI) calcd for C19H21N2O5S [M – H]
–
: 389.1177; found: 389.1185. 
 
4.4 Cyclic selenium-catalyzed enantioselective 
bromoaminocyclization reaction 
General Procedure. To a solution of sulfonamide 381 (0.03 mmol, 1.0 equiv) 
and cyclic selenium 331m (3.4 mg, 0.006 mmol, 0.2 equiv) in CH2Cl2 (0.8 mL) 
and toluene (0.8 mL) at –78 oC under N2 was added N-bromophthalimide (7.2 
mg, 0.033 mmol, 1.1 equiv) in the absence of light. The resultant mixture was 
stirred at –78 oC for 6 d in the absence of light. The reaction was quenched 
with saturated aqueous Na2SO3 solution (2 mL) at –78 
o
C and then warmed to 
25 
o
C. The solution was diluted with water (3 mL) and extracted with CH2Cl2 
(5 mL × 3). The combined extracts were washed with brine (5 mL), dried over 
sodium sulphate, filtered and concentrated in vacuo. The residue was 








White solid; mp 190.3 °C (decomposed); [] 28D  1.7 (c 1.1, CHCl3, 92% ee); IR 




H NMR (500 MHz, CDCl3): 
δ 8.15 (d, J = 8.2 Hz, 1H), 7.78 (t, J = 1.8 Hz, 1H), 7.46 (d, J = 8.2 Hz, 1H), 
7.37-7.31 (m, 3H), 7.20-7.16 (m, 3H), 6.04 (q, J = 6.9 Hz, 1H), 3.90 (dt, J = 
10.1, 6.9 Hz, 1H), 3.64-3.60 (m, 1H), 2.83 (ddd, J = 13.6, 11.4, 8.4 Hz, 1H), 
2.42 (ddd, J = 13.6, 8.1, 1.9 Hz, 1H), 2.26-2.19 (m, 1H), 2.16-2.05 (m, 1H), 
1.67 (d, J = 6.8 Hz, 3H); 
13
C NMR (125 MHz, CDCl3):  147.7, 142.7, 138.2, 
131.7, 129.4, 128.5, 128.1, 127.7, 125.9, 121.6, 73.9, 58.7, 51.5, 36.7, 24.8, 
22.7; HRMS (ESI) calcd for C18H19BrN2NaO4S m/z [M + Na]
+
: 461.0141; 
found: 461.0150. HPLC (Daicel Chiralpak IB, i-PrOH/n-hexane = 15/85, 0.6 











White solid; mp 192.8 °C (decomposed); [] 28D  13.2 (c 1.0, CHCl3, 91% ee); 




H NMR (500 MHz, 
CDCl3): 8.15 (d, J = 8.2 Hz, 1H), 7.76 (t, J = 1.4 Hz, 1H), 7.44 (d, J = 7.7 Hz, 
1H), 7.36 (t, J = 8.0 Hz, 1H), 7.29-7.26 (m, 2H), 7.19-7.16 (m, 3H), 5.71 (dd, 
J = 11.0, 1.0 Hz, 1H), 3.91 (dt, J = 10.1, 6.9 Hz, 1H), 3.64-3.60 (m, 1H), 2.82 
(ddd, J = 13.6, 11.4, 8.5 Hz, 1H), 2.38 (ddd, J = 13.6, 8.1, 1.9 Hz, 1H), 2.26-
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2.20 (m, 1H), 2.17-2.05 (m, 1H), 1.84-1.76 (m, 1H), 1.67-1.58 (m, 1H), 1.18 (t, 
J = 7.1 Hz, 3H); 
13
C NMR (125 MHz, CDCl3):  147.7, 142.8, 138.8, 131.7, 
129.4, 128.5, 128.0, 127.5, 125.9, 121.6, 73.8, 68.6, 51.5, 37.1, 28.8, 25.0, 
12.8; HRMS (ESI) calcd for C19H21BrN2NaO4S m/z [M + Na]
+
: 475.0298; 
found: 475.3010; HPLC (Daicel Chiralpak IA, i-PrOH/n-hexane = 15/85, 0.6 









White solid; mp 181.7 °C (decomposed); [] 28D  3.9 (c 0.9, CHCl3, 90% ee); IR 




H NMR (500 MHz, CDCl3): 
δ 8.15 (d, J = 8.2 Hz, 1H), 7.76 (s, 1H), 7.44 (d, J = 8.0 Hz, 1H), 7.36 (t, J = 
8.0 Hz, 1H), 7.30-7.27 (m, 2H), 7.21-7.16 (m, 3H), 5.81 (d, J = 10.6 Hz, 1H), 
3.91 (dt, J = 10.1, 6.8 Hz, 1H), 3.64-3.60 (m, 1H), 2.82 (ddd, J = 13.6, 11.5, 
8.5 Hz, 1H), 2.39 (ddd, J = 13.5, 7.9, 1.5 Hz, 1H), 2.26-2.19 (m, 1H), 2.15-
2.05 (m, 1H), 1.85-1.77 (m, 1H), 1.72-1.50 (m, 3H), 0.93 (t, J = 7.2 Hz, 3H); 
13
C NMR (100 MHz, CDCl3):  147.7, 142.8, 138.8, 131.7, 129.4, 128.5, 
128.0, 127.6, 125.9, 121.6, 73.7, 66.2, 51.5, 37.3, 37.1, 25.0, 21.3, 13.5; 
HRMS (ESI) calcd for C20H23BrN2NaO4S m/z [M + Na]
+
: 489.0454; found: 
489.0463; HPLC (Daicel Chiralpak IA, i-PrOH/n-hexane = 10/90, 0.6 mL/min, 







Colorless oil; [] 28D  4.4 (c 1.2, CHCl3, 90% ee); IR (KBr): 2958, 1533, 1351, 




H NMR (500 MHz, CDCl3): 8.15 (d, J = 8.2 Hz, 1H), 
7.76 (t, J = 1.8 Hz, 1H), 7.44 (d, J = 7.8 Hz, 1H), 7.36 (t, J = 8.0 Hz, 1H), 
7.29-7.26 (m, 2H), 7.20-7.16 (m, 3H), 5.78 (dd, J = 10.7, 0.9 Hz, 1H), 3.91 (dt, 
J = 10.1, 6.9 Hz, 1H), 3.64-3.60 (m, 1H), 2.82 (ddd, J = 13.7, 11.4, 8.4 Hz, 
1H), 2.39 (ddd, J = 13.6, 8.1, 1.8 Hz, 1H), 2.26-2.19 (m, 1H), 2.15-2.05 (m, 
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1H), 1.81-1.68 (m, 2H), 1.66-1.58 (m, 1H), 1.55-1.48 (m, 1H), 1.40-1.22 (m, 
2H), 0.89 (t, J = 7.3 Hz, 3H); 
13
C NMR (75 MHz, CDCl3):  147.7, 142.8, 
138.8, 131.7, 129.4, 128.5, 128.0, 127.6, 125.9, 121.6, 73.8, 66.6, 51.5, 37.1, 
35.0, 30.3, 24.9, 22.1, 13.9; HRMS (ESI) calcd for C21H25BrN2NaO4S m/z [M 
+ Na]
+
: 503.0611; found: 503.0620; HPLC (Daicel Chiralpak IA, i-PrOH/n-











Colorless oil; [] 28D  8.0 (c 1.2, CHCl3, 84% ee); IR (KBr): 2956, 1535, 1347, 




H NMR (500 MHz, CDCl3): δ 8.15 (ddd, J = 8.1, 2.1, 
1.0 Hz, 1H), 7.78 (s, 1H), 7.45 (d, J = 7.8 Hz, 1H), 7.37-7.33 (m, 3H), 7.22-
7.16 (m, 3H), 5.95 (d, J = 11.6, 1H), 3.89 (dt, J = 10.2, 6.7 Hz, 1H), 3.63-3.59 
(m, 1H), 2.83 (ddd, J = 13.3, 12.0, 8.4 Hz, 1H), 2.41 (dd, J = 13.6, 7.6 Hz, 
1H), 2.24-2.05 (m, 3H), 1.64 (ddd, J = 15.0, 11.9, 3.2 Hz, 1H), 1.39 (ddd, J = 
14.9, 10.5, 1.1 Hz, 1H), 1.05 (d, J = 6.6 Hz, 3H), 0.90 (d, J = 6.7 Hz, 3H); 
13
C 
NMR (125 MHz, CDCl3):  147.7, 142.9, 138.4, 131.7, 129.4, 128.5, 128.1, 
127.9, 125.9, 121.5, 73.8, 64.8, 51.5, 43.4, 37.0, 26.6, 25.0, 23.6, 20.7; HRMS 
(ESI) calcd for C21H25BrN2NaO4S m/z [M + Na]
+
: 503.0611; found: 503.0620; 
HPLC (Daicel Chiralpak IB, i-PrOH/n-hexane = 15/85, 0.6 mL/min, 254 nm) 








White solid; mp 189.7 °C (decomposed);  [] 28D  81.5 (c 0.9, CHCl3, 60% ee); 




H NMR (500 MHz, 
CDCl3): δ 8.17 (d, J = 8.1 Hz, 1H), 7.80 (s, 1H), 7.49-7.21 (m, 12H), 6.04 (d, 
J = 10.7 Hz, 1H), 3.92 (dt, J = 10.2, 6.8 Hz, 1H), 3.66-3.63 (m, 1H), 3.18 (d, J 
= 15.3 Hz, 1H), 2.97 (ddd, J = 13.5, 11.7, 8.3 Hz, 1H), 2.86 (dd, J = 15.3, 





(100 MHz, CDCl3):  147.7, 142.8, 138.3, 137.9, 131.7, 129.5, 129.0, 128.7, 
128.5, 128.3, 127.8, 127.0, 126.0, 121.6, 73.8, 66.3, 51.6, 41.0, 37.0, 25.0; 
HRMS (ESI) calcd for C24H23BrN2NaO4S m/z [M + Na]
+
: 537.0454; found: 
537.0458; HPLC (Daicel Chiralpak IB, i-PrOH/n-hexane = 15/85, 0.6 mL/min, 










Colorless oil; [] 28D  -3.6 (c 1.5, CHCl3, 83% ee); IR (Neat): IR (KBr): 2925, 




H NMR (500 MHz, CDCl3): δ 8.13 (d, J 
= 7.9 Hz, 1H), 7.69 (s, 1H), 7.37-6.99 (m, 12H), 5.77 (dd, J = 10.2, 1.9 Hz, 
1H), 3.91 (dt, J = 10.2, 6.8 Hz, 1H), 3.62-3.58 (m, 1H), 3.06 (ddd, J = 13.1, 
7.8, 4.9 Hz, 1H), 2.89-2.79 (m, 2H), 2.36 (dd, J = 12.5, 8.3 Hz, 1H), 2.25-2.19 
(m, 1H), 2.13-1.91 (m, 3H); 
13
C NMR (125 MHz, CDCl3):  147.7, 142.7, 
140.4, 138.4, 131.7, 129.4, 128.8, 128.6, 128.4, 128.0, 127.6, 126.5, 125.9, 
121.5, 73.5, 65.2, 51.4, 37.2, 37.1, 33.8, 25.0; HRMS (ESI) calcd for 
C25H25BrN2NaO4S m/z [M + Na]
+
: 551.0611; found: 551.0631; HPLC (Daicel 
Chiralpak IB, i-PrOH/n-hexane = 15/85, 0.6 mL/min, 254 nm) t1= 21.0 min 








White solid; mp 161.5-163.4 °C;  [] 28D  12.9 (c 1.3, CHCl3, 84% ee); IR (KBr): 




H NMR (400 MHz, CDCl3): δ 8.16 
(ddd, J = 8.1, 2.2, 1.2 Hz, 1H), 7.76 (t, J = 1.9 Hz, 1H), 7.45 (ddd, J = 7.8, 1.6, 
1.2 Hz, 1H), 7.36 (t, J = 8.0 Hz, 1H), 7.32-7.29 (m, 2H), 7.20-7.16 (m, 3H), 
5.98 (tdd, J = 16.8, 10.2, 6.60 Hz, 1H), 5.82 (dd J = 10.9, 1.7 Hz, 1H), 5.16 
(qdd, J = 23.8, 17.0, 1.4 Hz, 2H), 3.92 (dt, J = 10.1, 6.8 Hz, 1H), 3.66-3.61 (m, 
1H), 2.83 (ddd, J = 13.6, 11.3, 8.4 Hz, 1H), 2.58 (qdd, J = 15.6, 6.8, 1.6 Hz, 
1H), 2.45-2.36 (m, 2H), 2.29-2.20 (m, 1H), 2.18-2.05 (m, 1H); 
13
C NMR (100 
MHz, CDCl3):  147.7, 142.7, 138.5, 134.5, 131.7, 129.5, 128.5, 128.2, 127.6, 
125.9, 121.6, 117.6, 73.6, 64.5, 51.5, 39.7, 37.2, 24.9; HRMS (ESI) calcd for 
C20H21BrN2NaO4S m/z [M + Na]
+
: 487.0298; found: 487.0314; HPLC (Daicel 
Chiralpak IB, i-PrOH/n-hexane = 15/85, 0.6 mL/min, 254 nm) t1= 18.6 min 








Colorless oil; [] 28D  16.5 (c 1.0, CHCl3, 90% ee); IR (KBr): 2955, 1540, 1351, 






H NMR (500 MHz, CDCl3): δ 8.15 (d, J = 8.2 
Hz, 1H), 7.76 (t, J = 1.8 Hz, 1H), 7.44 (d, J = 7.7 Hz, 1H), 7.36 (t, J = 8.0 Hz, 
1H), 7.30-7.27 (m, 2H), 7.20-7.16 (m, 3H), 5.83-5.74 (m, 2H), 5.15-5.06 (m, 
2H), 3.91 (dt, J = 10.1, 6.8 Hz, 1H), 3.64-3.60 (m, 1H), 2.83 (ddd, J = 13.6, 
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11.6, 8.5 Hz, 1H), 2.53-2.06 (m, 5H), 1.84-1.68 (m, 2H); 
13
C NMR (75 MHz, 
CDCl3):  147.7, 142.8, 138.6, 136.5, 131.7, 129.4, 128.5, 128.1, 127.7, 125.9, 
121.6, 116.5, 73.7, 65.5, 51.5, 37.2, 34.4, 32.0, 25.0; HRMS (ESI) calcd for 
C21H23BrN2NaO4S m/z [M + Na]
+
: 501.0454; found: 501.0462; HPLC (Daicel 
Chiralpak IB, i-PrOH/n-hexane = 15/85, 0.6 mL/min, 254 nm) t1= 17.5 min 









White solid; mp 203.3 °C (decomposed); [] 26D  20.9 (c 0.9, CHCl3, 79% ee); 




H NMR (500 MHz, 
CD2Cl2): δ 8.21 (d, J = 8.2 Hz, 1H), 8.02 (s, 1H), 7.64 (d, J = 7.4 Hz, 1H), 
7.46 (t, J = 8.0 Hz, 1H), 7.31-7.03 (m, 11H), 3.80 (q, J = 8.2 Hz, 1H), 3.65 (dt, 
J = 9.2, 2.7 Hz, 1H), 3.33 (ddd, J = 13.0, 11.4, 8.3 Hz, 1H), 2.75 (ddd, J = 
13.1, 7.8, 2.1 Hz, 1H), 2.26-2.20 (m, 1H), 2.12-2.02 (m, 1H); 
13
C NMR (125 
MHz, CD2Cl2):  148.1, 142.6, 139.5, 138.4, 132.5, 130.1, 129.9, 128.6 (two 
peaks), 128.5, 128.3, 128.2, 126.6, 122.2, 76.2, 64.7, 51.4, 38.6, 24.4; HRMS 
(ESI) calcd for C23H21BrN2NaO4S m/z [M + Na]
+
: 523.0298; found: 523.0313; 
HPLC (Daicel Chiralpak IB, i-PrOH/n-hexane = 15/85, 0.6 mL/min, 254 nm) 







White solid; mp 194.6 °C (decomposed); [] 28D  102.0 (c 0.8, CHCl3, 59% ee); 




H NMR (400 MHz, 
CDCl3): δ 8.24 (ddd, J = 8.1, 2.2, 1.2 Hz, 1H), 7.92 (t, J = 1.9 Hz, 1H), 7.51 
(dt, J = 7.6, 1.2 Hz, 1H), 7.43 (t, J = 8.0 Hz, 1H), 7.30-7.15 (m,  4H), 5.96 (q, 
J = 6.9 Hz, 1H), 3.87 (dt, J = 10.1, 6.8 Hz, 1H), 3.67-3.62 (m, 1H), 2.83 (ddd, 
J = 13.7, 11.5, 8.4 Hz, 1H), 2.37 (ddd, J = 13.7, 8.1, 1.9 Hz, 1H), 2.27-2.02 
(m, 2H), 1.64 (d, J = 6.9 Hz, 3H); 
13
C NMR (100 MHz, CDCl3):  147.7, 
142.8, 136.9, 134.3, 131.7, 129.6, 129.2, 128.6, 126.2, 121.5, 73.5, 58.0, 51.5, 
36.6, 24.8, 22.5; HRMS (ESI) calcd for C18H18BrClN2NaO4S m/z [M + Na]
+
: 
494.9751; found: 494.9772; HPLC (Daicel Chiralpak IE, i-PrOH/n-hexane = 









White solid; mp 127.4-129.3 °C; [] 28D  0.3 (c 0.7, CHCl3, 83% ee); IR (KBr): 




H NMR (500 MHz, CDCl3): δ 8.22 
(d, J = 8.2 Hz, 1H), 7.84 (t, J = 1.7 Hz, 1H), 7.55 (d, J = 7.8 Hz, 1H), 7.45 (t, 
J = 8.0 Hz, 1H), 7.31 (d, J = 8.0 Hz, 1H), 7.22-7.15 (m,  3H), 5.94 (q, J = 6.9 
Hz, 1H), 3.90 (dt, J = 10.1, 6.8 Hz, 1H), 3.68-3.64 (m, 1H), 2.83 (ddd, J = 
143 
 
13.8, 11.4, 8.4 Hz, 1H), 2.37 (ddd, J = 13.7, 8.1, 1.7 Hz, 1H), 2.27-2.07 (m, 
2H), 1.66 (d, J = 6.9 Hz, 3H);  
13
C NMR (125 MHz, CDCl3):  147.7, 142.7, 
140.3, 134.7, 131.6, 129.6 (two peaks), 128.3, 128.2, 126.3, 125.8, 121.3, 73.6, 
57.8, 51.6, 36.7, 24.7, 22.6; HRMS (ESI) calcd for C18H18BrClN2NaO4S m/z 
[M + Na]
+
: 494.9751; found: 494.9775; HPLC (Daicel Chiralpak IE, i-








White semi-solid; [] 26D  35.6 (c 1.0, CHCl3, 79% ee); IR (KBr): 2960, 1534, 




H NMR (500 MHz, CDCl3): 8.22 (d, J = 8.2 
Hz, 1H), 7.87 (s, 1H), 7.53 (d, J = 7.7 Hz, 1H), 7.43 (t, J = 8.0 Hz, 1H), 7.36 
(dd, J = 8.8, 5.1 Hz, 2H), 6.91 (t, J = 8.5 Hz, 2H), 5.98 (q, J = 6.8 Hz, 1H), 
3.84 (dt, J = 10.2, 6.8 Hz, 1H), 3.62-3.58 (m, 1H), 2.83 (ddd, J = 13.6, 11.8, 
8.4 Hz, 1H), 2.39 (dd, J = 13.8, 7.4 Hz, 1H), 2.24-2.19 (m, 1H), 2.13-2.01 (m, 
1H), 1.64 (d, J = 6.9 Hz, 3H); 
13
C NMR (125 MHz, CDCl3): δ 162.0 (d, J = 
250.1 Hz), 147.7, 142.8, 134.2 (d, J = 3.8 Hz), 131.8, 129.7 (d, J = 8.0 Hz), 
129.6, 126.2, 121.5, 115.3 (d, J = 21.3 Hz), 73.7, 58.3, 51.4, 36.6, 24.7, 22.5; 
HRMS (ESI) calcd for C18H18BrFN2NaO4S m/z [M + Na]
+
: 479.0047; found: 
479.0044; HPLC (Daicel Chiralpak IB, i-PrOH/n-hexane = 15/85, 0.6 mL/min, 









Light yellow solid; mp 189.6 °C (decomposed); [] 26D  22.7 (c 1.0, CHCl3, 29% 




H NMR (500 MHz, 
CDCl3): δ 8.21 (dt, J = 6.5, 2.5 Hz, 1H), 7.99 (s, 1H), 7.48 (q, J = 8.8 Hz, 4H), 
7.38-7.34 (m, 2H), 6.01 (q, J = 6.9, 1H), 3.89 (dt, J = 10.1, 6.8 Hz, 1H), 3.69-
3.65 (m, 1H), 2.88 (ddd, J = 13.7, 11.5, 8.5 Hz, 1H), 2.42 (dd, J = 13.8, 6.7 
Hz, 1H), 2.24-2.30 (m, 1H), 2.19-2.08 (m, 1H), 1.65 (d, J = 6.9 Hz, 3H); 
13
C 
NMR (125 MHz, CDCl3):  147.6, 142.6, 142.3, 131.6, 130.3 (q, J = 32.9 Hz), 
129.7, 128.2, 126.3, 125.4 (q, J = 3.8 Hz), 123.5 (q, J = 272.4 Hz), 121.4, 
73.7, 57.5, 51.6, 36.6, 24.7, 22.5; HRMS (ESI) calcd for C19H18BrF3N2NaO4S 
m/z [M + Na]
+
: 529.0015; found: 529.0023; HPLC (Daicel Chiralpak IB, i-










White solid; mp 181.2 °C (decomposed); [] 25D  -8.4 (c 1.1, CHCl3, 95% ee); 




H NMR (500 MHz, 
CDCl3): δ 8.15 (d, J = 8.2, 1H), 7.72 (t, J = 1.8 Hz, 1H), 7.51 (d, J = 8.2, 1H), 
7.38 (t, J = 8.0 Hz, 1H), 7.10-6.93 (m, 4H), 6.01 (q, J = 6.9 Hz, 1H), 3.92 (dt, 
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J = 10.0, 6.8 Hz, 1H), 3.68-3.63 (m, 1H), 2.81 (ddd, J = 13.6, 11.1, 8.5 Hz, 
1H), 2.39 (ddd, J = 13.6, 8.2, 2.1 Hz, 1H), 2.26-2.06 (m, 5H), 1.67 (d, J = 6.8, 
3H); 
13
C NMR (125 MHz, CDCl3):  147.6, 142.8, 138.2, 138.1, 131.6, 129.3, 
128.7, 128.4, 128.2, 125.8, 124.8, 121.5, 73.7, 58.8, 51.7, 36.8, 24.9, 22.7, 
21.5; HRMS (ESI) calcd for C19H21BrN2NaO4S m/z [M + Na]
+
: 475.0298; 
found: 475.0302; HPLC (Daicel Chiralpak IB, i-PrOH/n-hexane = 15/85, 0.6 









White solid; mp 158.5 °C (decomposed); [] 28D  -49.3 (c 1.0, CHCl3, 51% ee); 




H NMR (500 MHz, 
CDCl3): δ 8.22 (dt, J = 6.8, 2.5 Hz, 1H), 7.66 (s, 1H), 7.40-7.36 (m, 3H), 7.23 
(d, J = 7.6, 1H), 7.10 (t, J = 7.5 Hz, 1H), 6.69 (d, J = 7.6, 1H),  6.12 (q, J = 
6.5 Hz, 1H), 4.27 (dt, J = 10.0, 5.5 Hz, 1H), 3.76 (dt, J = 9.9, 5.4 Hz, 1H), 
2.75-2.68 (m, 1H), 2.50-2.38 (m, 2H), 2.23-2.13 (m, 1H), 1.89 (d, J = 6.5, 3H), 
1.63 (s, 3H); 
13
C NMR (125 MHz, CDCl3):  147.6, 141.7, 137.0, 136.1, 133.1, 
131.9, 129.6, 129.3, 128.2, 126.0, 125.7, 121.8, 74.9, 60.6, 52.8, 35.1, 24.5, 
22.7, 21.6; HRMS (ESI) calcd for C19H21BrN2NaO4S m/z [M + Na]
+
: 
475.0298; found: 475.0299; HPLC (Daicel Chiralpak IB, i-PrOH/n-hexane = 







White solid; mp 179.2 °C (decomposed); [] 28D  -2.3 (c 0.9, CHCl3, 75% ee); 




H NMR (500 MHz, 
CDCl3): δ 8.17 (dd, J = 8.1, 1.7 Hz, 1H), 7.70 (t, J = 1.8 Hz 1H), 7.58 (d, J = 
8.0, 1H), 7.38 (t, J = 8.0 Hz, 1H), 7.19 (d, J = 8.3, 2H),  6.97 (d, J = 8.2, 2H),  
6.02 (q, J = 6.8 Hz, 1H), 3.88 (dt, J = 10.1, 6.8 Hz, 1H), 3.64-3.60 (m, 1H), 
2.80 (ddd, J = 13.6, 11.3, 8.4 Hz, 1H), 2.38 (ddd, J = 13.6, 8.0, 2.0 Hz, 1H), 
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2.25-2.17 (m, 4H), 2.14-2.03 (m, 1H), 1.66 (d, J = 6.9, 3H); 
13
C NMR (125 
MHz, CDCl3):  147.7, 142.9, 138.3, 135.2, 131.8, 129.3, 129.0, 127.7, 125.8, 
121.6, 73.7, 58.9, 51.5, 36.8, 24.9, 22.7, 20.7; HRMS (ESI) calcd for 
C19H21BrN2NaO4S m/z [M + Na]
+
: 475.0298; found: 475.0301; HPLC (Daicel 
Chiralpak IB, i-PrOH/n-hexane = 15/85, 0.6 mL/min, 254 nm) t1= 19.7 min 







Light yellow solid; mp 128.1 °C (decomposed); [] 26D  -55.0 (c 0.9, CHCl3, 2% 




H NMR (500 MHz, 
CDCl3): 8.20 (d, J = 8.2 Hz, 1H), 7.66 (s, 1H), 7.48 (d, J = 8.1 Hz, 1H), 7.41 
(t, J = 8.0 Hz, 1H), 7.19 (d, J = 8.8 Hz, 2H), 6.57 (d, J = 8.8 Hz, 2H), 5.55 (q, 
J = 6.6 Hz, 1H), 3.90 (dt, J = 9.8, 7.2 Hz, 1H), 3.75-3.69 (m, 4H), 2.85 (dt, J 
=14.5, 8.5 Hz, 1H), 2.43 (ddd, J = 14.5, 8.4, 6.0 Hz, 1H), 2.20-2.08 (m, 2H), 
2.01 (d, J = 6.6 Hz, 3H),; 
13
C NMR (125 MHz, CDCl3):  158.8, 147.7, 141.8, 
131.9, 131.6, 129.4, 129.1, 126.0, 121.9, 112.8, 72.7, 55.1, 52.6, 52.4, 39.2, 
24.8, 20.9; HRMS (ESI) calcd for C19H21BrN2NaO5S m/z [M + Na]
+
: 
491.0247; found: 491.0266; HPLC (Daicel Chiralpak IB, i-PrOH/n-hexane = 




4.5 Synthesis of 383–385  
 
Synthesis of (2R,3R)-2-methyl-1-((3-nitrophenyl)sulfonyl)-3-phenyl-
piperidin-3-ol (383)  
A solution of 375d (70 mg, 0.16 mmol, 1.0 eq) and silver trifluoroacetate (106 
mg, 0.48 mmol, 3.0 eq) in acetone (3 mL) and water (1 mL) was stirred at 60 
o
C for 8 h in the absence of light. After cooled to 25 
o
C, the solution was 
diluted with brine (2 mL) and stirred for 5 minutes. The mixture was filtered 
through a thin plug of celite and the residue was washed with EtOAc. The 
filtrate was extracted with EtOAc (5 mL × 3). The combined organic extracts 
were washed with brine, dried over sodium sulfate, and concentrated in vacuo. 
The residue was subject to flash column chromatography to give the desired 
product 383 (49 mg, 82%). 
White solid; mp 124.7-126.5 °C; [] 25D  - 68.3 (c 1.5, CHCl3, 92% ee); IR 




H NMR (500 MHz, 
CDCl3):  8.82 (d, J = 1.8 Hz, 1H), 8.39 (d, J = 8.2 Hz, 1H),  8.24 (d, J = 7.3 
Hz, 1H), 7.70 (t, J = 8.0 Hz, 1H), 7.47-7.28 (m, 5H), 4.27 (q, J = 6.9 Hz, 1H), 
3.79 (dd, J = 12.8, 2.8 Hz, 1H), 3.09 (dt, J = 13.4, 2.6 Hz, 1H), 2.35 (dt, J = 
13.6, 4.4 Hz, 1H), 2.02-1.91 (m, 1H), 1.81 (d, J = 13.7 Hz, 1H), 1.68 (d, J = 
13.6 Hz, 1H),  0.77 (d, J = 7.0 Hz, 3H); 
13
C NMR (125 MHz, CDCl3):  148.2, 
153 
 
144.1, 143.3, 132.8, 130.1, 128.6, 128.0, 126.7, 125.6, 122.6, 73.3, 59.3, 39.4, 
28.1, 20.5, 13.8; HRMS (ESI) calcd for C18H20N2NaO5S m/z [M + Na]
+
: 
399.0985; found: 399.0987; HPLC (Daicel Chiralpak IB, i-PrOH/n-hexane = 






tetrahydropyridine (384)  
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To the mixture of CH2Cl2 (3 mL) and pyridine (2 mL) at 0 
o
C was added 
SOCl2 (90 µL, 1.2 mmol, 15.0 eq) dropwise over 10 minutes, followed by the 
addition of a solution of 383 (30 mg, 0.08 mmol, 1.0 eq) in CH2Cl2 (1 mL). 
The resultant solution was heated to reflux for 12 h. After cooled to 25 
o
C, the 
solution was diluted with water (2 mL) and CH2Cl2 (5 mL). The organic layer 
was separated, and washed with aqueous HCl (2 M, 5 mL) and brine (5 mL). 
The organic phase was then dried over sodium sulfate, and concentrated in 
vacuo. The residue was subject to flash column chromatography to afford the 
desired product 384 (21 mg, 74%).   
White semi-solid; []  - 269.4 (c 0.8, CHCl3, 92% ee); IR (KBr): 2979, 1606, 




H NMR (500 MHz, CDCl3):  8.71 (t, J 
= 1.7 Hz, 1H), 8.34 (ddd, J = 8.2, 2.1, 1.0 Hz, 1H),  8.17 (d, J = 8.0 Hz, 1H), 
7.65 (t, J = 8.0 Hz, 1H), 7.33-7.22 (m, 5H), 5.71 (s, 1H), 5.01 (q, J = 6.5 Hz, 
1H), 3.97 (dd, J = 14.1, 6.2 Hz, 1H), 3.30 (ddd, J = 14.4, 11.5, 5.2 Hz, 1H), 
2.16-2.02 (m, 2H), 1.21 (d, J = 6.7 Hz, 3H); 
13
C NMR (125 MHz, CDCl3):  
148.2, 143.6, 140.4, 139.0, 132.1, 130.4, 128.7, 127.8, 126.8, 126.1, 122.3, 
122.0, 51.2, 37.3, 24.5, 19.4; HRMS (EI) calcd for C18H18N2O4S m/z [M]
+
: 
358.0987; found: 358.0986; HPLC (Daicel Chiralpak IB, i-PrOH/n-hexane = 







Synthesis of (S)-4-bromo-4-((S)-1-((3-nitrophenyl)sulfonyl)-2-phenyl- 
pyrrolidin-2-yl)butan-1-ol (385) 
To a solution of 382h (20 mg, 0.04 mmol, 1.0 eq) in THF (2 mL) at 0 
o
C was 
added BH3•THF (40 µL, 0.04 mmol, 1.0 eq). The resultant mixture was 
warmed to 25 
o
C and stirred for 1 h. Then the reaction was cooled to 0 
o
C, 
followed by the addition of aqueous NaOH solution (3.0 M, 10 µL) and H2O2 
(30% aqueous solution, 10 µL) successively. After stirred for 1 h at 25 
o
C, the 
resultant suspension was diluted with CH2Cl2 (10 mL), dried over sodium 
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sulfate, and concentrated in vacuo. The residue was subject to flash column 
chromatography to afford the desired product 385 (14 mg, 67%).  
Colorless oil; [] 25D  0.4 (c 1.0, CHCl3, 90% ee); IR (KBr): 3398, 2925, 1533, 




H NMR (500 MHz, CDCl3): δ 8.15 (ddd, J = 
8.1, 2.1, 1.0 Hz, 1H), 7.76 (s, 1H), 7.44 (d, J = 7.8 Hz, 1H), 7.36 (t, J = 8.0 Hz, 
1H), 7.30-7.17 (m, 5H), 5.80 (d, J = 10.6 Hz, 1H), 3.90 (dt, J = 10.1, 6.8 Hz, 
1H), 3.66-3.60 (m, 3H), 2.82 (ddd, J = 13.6, 11.5, 8.4 Hz, 1H), 2.40 (ddd, J = 
13.5, 8.0, 1.5 Hz, 1H), 2.26-2.20 (m, 1H), 2.16-2.05 (m, 1H), 1.90-1.51 (m, 
6H); 
13
C NMR (100 MHz, CDCl3):  147.7, 142.8, 138.7, 131.7, 129.5, 128.5, 
128.1, 127.5, 125.9, 121.6, 73.7, 66.3, 62.6, 51.5, 37.1, 35.1, 31.9, 24.9, 24.5; 
HRMS (ESI) calcd for C21H25BrN2NaO5S m/z [M + Na]
+
: 519.0560; found: 
519.0571; HPLC (Daicel Chiralpak IB, i-PrOH/n-hexane = 15/85, 0.6 mL/min, 
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*** Acquisition  Parameters ***
BF1 :    300.1300000 MHz
LOCNUC : 2H
NS :              8
O1 :        1853.43 Hz
PULPROG : zg30
SFO1 :    300.1318534 MHz
SOLVENT : CDCl3
SW :        17.9519 ppm
*** Processing Parameters ***
LB :           0.30 Hz
PHC0 :        319.462 degree
PHC1 :          3.094 degree






























































































































































































































*** Acquisition  Parameters ***
BF1 :    500.1300000 MHz
LOCNUC : 2H
NS :              8
O1 :        3088.51 Hz
PULPROG : zg30
SFO1 :    500.1330885 MHz
SOLVENT : CDCl3
SW :        20.6557 ppm
*** Processing Parameters ***
LB :           0.30 Hz
PHC0 :        137.686 degree













































































































































































*** Acquisition  Parameters ***
BF1 :    500.1300000 MHz
LOCNUC : 2H
NS :              8
O1 :        3088.51 Hz
PULPROG : zg30
SFO1 :    500.1330885 MHz
SOLVENT : CDCl3
SW :        20.6557 ppm
*** Processing Parameters ***
LB :           0.30 Hz
PHC0 :        354.138 degree
















































































































































































































*** Acquisition  Parameters ***
BF1 :    500.1300000 MHz
LOCNUC : 2H
NS :              8
O1 :        3088.51 Hz
PULPROG : zg30
SFO1 :    500.1330885 MHz
SOLVENT : CDCl3
SW :        20.6557 ppm
*** Processing Parameters ***
LB :           0.30 Hz
PHC0 :        246.892 degree


































































































*** Acquisition  Parameters ***
BF1 :    125.7577890 MHz
LOCNUC : 2H
NS :             65
O1 :       13204.57 Hz
PULPROG : zgpg30
SFO1 :    125.7709936 MHz
SOLVENT : CDCl3
SW :       238.7675 ppm
*** Processing Parameters ***
LB :           1.00 Hz
PHC0 :        155.860 degree


































































































































































































































































*** Acquisition  Parameters ***
BF1 :    500.1300000 MHz
LOCNUC : 2H
NS :              8
O1 :        3088.51 Hz
PULPROG : zg30
SFO1 :    500.1330885 MHz
SOLVENT : CDCl3
SW :        20.6557 ppm
*** Processing Parameters ***
LB :           0.30 Hz
PHC0 :        138.803 degree


































































































*** Acquisition  Parameters ***
BF1 :    125.7577890 MHz
LOCNUC : 2H
NS :             40
O1 :       13204.57 Hz
PULPROG : zgpg30
SFO1 :    125.7709936 MHz
SOLVENT : CDCl3
SW :       238.7675 ppm
*** Processing Parameters ***
LB :           1.00 Hz
PHC0 :         34.186 degree



















































































































































































































































*** Acquisition  Parameters ***
BF1 :    500.1300000 MHz
LOCNUC : 2H
NS :              8
O1 :        3088.51 Hz
PULPROG : zg30
SFO1 :    500.1330885 MHz
SOLVENT : CDCl3
SW :        20.6557 ppm
*** Processing Parameters ***
LB :           0.30 Hz
PHC0 :        252.013 degree



















































































































*** Acquisition  Parameters ***
BF1 :    125.7577890 MHz
LOCNUC : 2H
NS :             62
O1 :       13204.57 Hz
PULPROG : zgpg30
SFO1 :    125.7709936 MHz
SOLVENT : CDCl3
SW :       238.7675 ppm
*** Processing Parameters ***
LB :           1.00 Hz
PHC0 :         33.909 degree













































































































































































































































































































































*** Acquisition  Parameters ***
BF1 :    500.1300000 MHz
LOCNUC : 2H
NS :              8
O1 :        3088.51 Hz
PULPROG : zg30
SFO1 :    500.1330885 MHz
SOLVENT : CDCl3
SW :        20.6557 ppm
*** Processing Parameters ***
LB :           0.30 Hz
PHC0 :        267.846 degree







































































































































*** Acquisition  Parameters ***
BF1 :    125.7577890 MHz
LOCNUC : 2H
NS :            133
O1 :       13204.57 Hz
PULPROG : zgpg30
SFO1 :    125.7709936 MHz
SOLVENT : CDCl3
SW :       238.7675 ppm
*** Processing Parameters ***
LB :           1.00 Hz
PHC0 :         21.793 degree























































































































































































































































































































































*** Acquisition  Parameters ***
BF1 :    500.1300000 MHz
LOCNUC : 2H
NS :              8
O1 :        3088.51 Hz
PULPROG : zg30
SFO1 :    500.1330885 MHz
SOLVENT : CDCl3
SW :        20.6557 ppm
*** Processing Parameters ***
LB :           0.30 Hz
PHC0 :        263.305 degree













































































































































*** Acquisition  Parameters ***
BF1 :    125.7577890 MHz
LOCNUC : 2H
NS :            162
O1 :       13204.57 Hz
PULPROG : zgpg30
SFO1 :    125.7709936 MHz
SOLVENT : CDCl3
SW :       238.7675 ppm
*** Processing Parameters ***
LB :           1.00 Hz
PHC0 :         28.216 degree





























































































































































































































































































































































































































*** Acquisition  Parameters ***
BF1 :    500.2300000 MHz
LOCNUC : 2H
NS :              8
O1 :        2751.27 Hz
PULPROG : zg
SFO1 :    500.2327513 MHz
SOLVENT : CDCl3
SW :        15.0080 ppm
*** Processing Parameters ***
LB :           0.10 Hz
PHC0 :        411.516 degree


















































































































































*** Acquisition  Parameters ***
BF1 :    125.7577890 MHz
LOCNUC : 2H
NS :            264
O1 :       13204.57 Hz
PULPROG : zgpg30
SFO1 :    125.7709936 MHz
SOLVENT : CDCl3
SW :       238.7675 ppm
*** Processing Parameters ***
LB :           1.00 Hz
PHC0 :         22.737 degree




















































































































































































































































































































































































































































































*** Acquisition  Parameters ***
BF1 :    500.2300000 MHz
LOCNUC : 2H
NS :              8
O1 :        2751.27 Hz
PULPROG : zg
SFO1 :    500.2327513 MHz
SOLVENT : CDCl3
SW :        15.0080 ppm
*** Processing Parameters ***
LB :           0.10 Hz
PHC0 :        655.756 degree
























































































































































*** Acquisition  Parameters ***
BF1 :     75.4677490 MHz
LOCNUC : 2H
NS :           2343
O1 :        7924.11 Hz
PULPROG : zgpg30
SFO1 :     75.4756731 MHz
SOLVENT : CDCl3
SW :       238.2968 ppm
*** Processing Parameters ***
LB :           1.00 Hz
PHC0 :        113.867 degree




























































































































































































































































































































































*** Acquisition  Parameters ***
BF1 :    500.1300000 MHz
LOCNUC : 2H
NS :              8
O1 :        3088.51 Hz
PULPROG : zg30
SFO1 :    500.1330885 MHz
SOLVENT : CDCl3
SW :        20.6557 ppm
*** Processing Parameters ***
LB :           0.30 Hz
PHC0 :        263.567 degree



















































































































































*** Acquisition  Parameters ***
BF1 :    125.7577890 MHz
LOCNUC : 2H
NS :            111
O1 :       13204.57 Hz
PULPROG : zgpg30
SFO1 :    125.7709936 MHz
SOLVENT : CDCl3
SW :       238.7675 ppm
*** Processing Parameters ***
LB :           1.00 Hz
PHC0 :         31.408 degree












































































































































































*** Acquisition  Parameters ***
BF1 :    125.7577890 MHz
LOCNUC : 2H
NS :            121
O1 :       13204.57 Hz
PULPROG : zgpg30
SFO1 :    125.7709936 MHz
SOLVENT : CDCl3
SW :       238.7675 ppm
*** Processing Parameters ***
LB :           1.00 Hz
PHC0 :        151.518 degree




























































































































































































































































































































































*** Acquisition  Parameters ***
BF1 :    500.1300000 MHz
LOCNUC : 2H
NS :              8
O1 :        3088.51 Hz
PULPROG : zg30
SFO1 :    500.1330885 MHz
SOLVENT : CDCl3
SW :        20.6557 ppm
*** Processing Parameters ***
LB :           0.30 Hz
PHC0 :        263.478 degree









































































































































































*** Acquisition  Parameters ***
BF1 :    125.7577890 MHz
LOCNUC : 2H
NS :            109
O1 :       13204.57 Hz
PULPROG : zgpg30
SFO1 :    125.7709936 MHz
SOLVENT : CDCl3
SW :       238.7675 ppm
*** Processing Parameters ***
LB :           1.00 Hz
PHC0 :        150.077 degree






























































































































































*** Acquisition  Parameters ***
BF1 :    125.7577890 MHz
LOCNUC : 2H
NS :            172
O1 :       13204.57 Hz
PULPROG : zgpg30
SFO1 :    125.7709936 MHz
SOLVENT : CDCl3
SW :       238.7675 ppm
*** Processing Parameters ***
LB :           1.00 Hz
PHC0 :        160.775 degree



















































































































































































































































































































































































































*** Acquisition  Parameters ***
BF1 :    500.1300000 MHz
LOCNUC : 2H
NS :              8
O1 :        3088.51 Hz
PULPROG : zg30
SFO1 :    500.1330885 MHz
SOLVENT : CDCl3
SW :        20.6557 ppm
*** Processing Parameters ***
LB :           0.30 Hz
PHC0 :         27.848 degree



























































































































































*** Acquisition  Parameters ***
BF1 :    125.7577890 MHz
LOCNUC : 2H
NS :          12328
O1 :       13204.57 Hz
PULPROG : zgpg30
SFO1 :    125.7709936 MHz
SOLVENT : CDCl3
SW :       238.7675 ppm
*** Processing Parameters ***
LB :           1.00 Hz
PHC0 :         27.525 degree






































































































































































*** Acquisition  Parameters ***
BF1 :    125.7577890 MHz
LOCNUC : 2H
NS :             96
O1 :       13204.57 Hz
PULPROG : zgpg30
SFO1 :    125.7709936 MHz
SOLVENT : CDCl3
SW :       238.7675 ppm
*** Processing Parameters ***
LB :           1.00 Hz
PHC0 :        180.057 degree
















































































































































































































































































































































































*** Acquisition  Parameters ***
BF1 :    500.2300000 MHz
LOCNUC : 2H
NS :              8
O1 :        2751.27 Hz
PULPROG : zg
SFO1 :    500.2327513 MHz
SOLVENT : CDCl3
SW :        15.0080 ppm
*** Processing Parameters ***
LB :           0.10 Hz
PHC0 :        654.740 degree






































































































































*** Acquisition  Parameters ***
BF1 :    125.7577890 MHz
LOCNUC : 2H
NS :            100
O1 :       13204.57 Hz
PULPROG : zgpg30
SFO1 :    125.7709936 MHz
SOLVENT : CDCl3
SW :       238.7675 ppm
*** Processing Parameters ***
LB :           1.00 Hz
PHC0 :         23.008 degree


















































































































































































































































































































































*** Acquisition  Parameters ***
BF1 :    500.1300000 MHz
LOCNUC : 2H
NS :              8
O1 :        3088.51 Hz
PULPROG : zg30
SFO1 :    500.1330885 MHz
SOLVENT : CDCl3
SW :        20.6557 ppm
*** Processing Parameters ***
LB :           0.30 Hz
PHC0 :        263.105 degree





















































































































































*** Acquisition  Parameters ***
BF1 :    125.7577890 MHz
LOCNUC : 2H
NS :            106
O1 :       13204.57 Hz
PULPROG : zgpg30
SFO1 :    125.7709936 MHz
SOLVENT : CDCl3
SW :       238.7675 ppm
*** Processing Parameters ***
LB :           1.00 Hz
PHC0 :        124.047 degree











































































































































































































































































*** Acquisition  Parameters ***
BF1 :    500.1300000 MHz
LOCNUC : 2H
NS :              8
O1 :        3088.51 Hz
PULPROG : zg30
SFO1 :    500.1330885 MHz
SOLVENT : CDCl3
SW :        20.6557 ppm
*** Processing Parameters ***
LB :           0.30 Hz
PHC0 :        299.328 degree




























































































































































*** Acquisition  Parameters ***
LOCNUC : 2H
NS :            152
NUCLEUS : off
O1 :       13204.57 Hz
PULPROG : zgpg30
SFO1 :    125.7709936 MHz
SOLVENT : CDCl3
SW :       238.7675 ppm
TD :          65536
TE :          297.9 K
*** Processing Parameters ***
LB :           1.00 Hz
SF :    125.7577930 MHz

























































































































































































































































*** Acquisition  Parameters ***
BF1 :    500.1300000 MHz
LOCNUC : 2H
NS :              8
O1 :        3088.51 Hz
PULPROG : zg30
SFO1 :    500.1330885 MHz
SOLVENT : CDCl3
SW :        20.6557 ppm
*** Processing Parameters ***
LB :           0.30 Hz
PHC0 :        300.547 degree













































































































































































































*** Acquisition  Parameters ***
BF1 :    125.7577890 MHz
LOCNUC : 2H
NS :            781
O1 :       13204.57 Hz
PULPROG : zgpg30
SFO1 :    125.7709936 MHz
SOLVENT : CDCl3
SW :       238.7675 ppm
*** Processing Parameters ***
LB :           1.00 Hz
PHC0 :        184.127 degree












































































































































































































































































*** Acquisition  Parameters ***
BF1 :    500.1300000 MHz
LOCNUC : 2H
NS :              8
O1 :        3088.51 Hz
PULPROG : zg30
SFO1 :    500.1330885 MHz
SOLVENT : CDCl3
SW :        20.6557 ppm
*** Processing Parameters ***
LB :           0.30 Hz
PHC0 :        264.961 degree



























































































































































*** Acquisition  Parameters ***
BF1 :    125.7577890 MHz
LOCNUC : 2H
NS :            141
O1 :       13204.57 Hz
PULPROG : zgpg30
SFO1 :    125.7709936 MHz
SOLVENT : CDCl3
SW :       238.7675 ppm
*** Processing Parameters ***
LB :           1.00 Hz
PHC0 :         39.910 degree











































































































































































































































































































































































*** Acquisition  Parameters ***
BF1 :    500.2300000 MHz
LOCNUC : 2H
NS :              8
O1 :        2751.27 Hz
PULPROG : zg
SFO1 :    500.2327513 MHz
SOLVENT : CDCl3
SW :        15.0080 ppm
*** Processing Parameters ***
LB :           0.10 Hz
PHC0 :        523.939 degree


























































































































































*** Acquisition  Parameters ***
BF1 :    125.7577890 MHz
LOCNUC : 2H
NS :            101
O1 :       13204.57 Hz
PULPROG : zgpg30
SFO1 :    125.7709936 MHz
SOLVENT : CDCl3
SW :       238.7675 ppm
*** Processing Parameters ***
LB :           1.00 Hz
PHC0 :        160.626 degree
































































































































































































































































































*** Acquisition  Parameters ***
BF1 :    500.2300000 MHz
LOCNUC : 2H
NS :              8
O1 :        2751.27 Hz
PULPROG : zg
SFO1 :    500.2327513 MHz
SOLVENT : CDCl3
SW :        15.0080 ppm
*** Processing Parameters ***
LB :           0.10 Hz
PHC0 :        422.139 degree












































































































































*** Acquisition  Parameters ***
BF1 :    125.7577890 MHz
LOCNUC : 2H
NS :            162
O1 :       13204.57 Hz
PULPROG : zgpg30
SFO1 :    125.7709936 MHz
SOLVENT : CDCl3
SW :       238.7675 ppm
*** Processing Parameters ***
LB :           1.00 Hz
PHC0 :         38.455 degree



























































































































































































































































































*** Acquisition  Parameters ***
BF1 :    500.1300000 MHz
LOCNUC : 2H
NS :              8
O1 :        3088.51 Hz
PULPROG : zg30
SFO1 :    500.1330885 MHz
SOLVENT : CDCl3
SW :        20.6557 ppm
*** Processing Parameters ***
LB :           0.30 Hz
PHC0 :        300.245 degree













































































































































*** Acquisition  Parameters ***
BF1 :    125.7577890 MHz
LOCNUC : 2H
NS :             73
O1 :       13204.57 Hz
PULPROG : zgpg30
SFO1 :    125.7709936 MHz
SOLVENT : CDCl3
SW :       238.7675 ppm
*** Processing Parameters ***
LB :           1.00 Hz
PHC0 :        186.337 degree




















































































































































































































































































































































































































































































*** Acquisition  Parameters ***
BF1 :    500.1300000 MHz
LOCNUC : 2H
NS :              8
O1 :        3088.51 Hz
PULPROG : zg30
SFO1 :    500.1330885 MHz
SOLVENT : CDCl3
SW :        20.6557 ppm
*** Processing Parameters ***
LB :           0.30 Hz
PHC0 :         26.110 degree





































































































































*** Acquisition  Parameters ***
BF1 :    125.7577890 MHz
LOCNUC : 2H
NS :          12465
O1 :       13204.57 Hz
PULPROG : zgpg30
SFO1 :    125.7709936 MHz
SOLVENT : CDCl3
SW :       238.7675 ppm
*** Processing Parameters ***
LB :           1.00 Hz
PHC0 :         32.208 degree








































































































































































































































































































































































































































































































*** Acquisition  Parameters ***
BF1 :    500.1300000 MHz
LOCNUC : 2H
NS :              8
O1 :        3088.51 Hz
PULPROG : zg30
SFO1 :    500.1330885 MHz
SOLVENT : CDCl3
SW :        20.6557 ppm
*** Processing Parameters ***
LB :           0.30 Hz
PHC0 :         26.595 degree











































































































































*** Acquisition  Parameters ***
BF1 :    125.7577890 MHz
LOCNUC : 2H
NS :           5395
O1 :       13204.57 Hz
PULPROG : zgpg30
SFO1 :    125.7709936 MHz
SOLVENT : CDCl3
SW :       238.7675 ppm
*** Processing Parameters ***
LB :           1.00 Hz
PHC0 :         23.585 degree






























































































































































































































































































































































































































































































*** Acquisition  Parameters ***
BF1 :    500.1300000 MHz
LOCNUC : 2H
NS :              8
O1 :        3088.51 Hz
PULPROG : zgpr
SFO1 :    500.1330885 MHz
SOLVENT : CDCl3
SW :        20.6557 ppm
*** Processing Parameters ***
LB :           0.30 Hz
PHC0 :        282.533 degree

















































































































































*** Acquisition  Parameters ***
BF1 :    100.6127690 MHz
LOCNUC : 2H
NS :           3797
O1 :       11067.40 Hz
PULPROG : zgpg30
SFO1 :    100.6238364 MHz
SOLVENT : CDCl3
SW :       238.8943 ppm
*** Processing Parameters ***
LB :           1.00 Hz
PHC0 :         94.667 degree

















































































































































































































































































































































































































































































































*** Acquisition  Parameters ***
BF1 :    500.1300000 MHz
LOCNUC : 2H
NS :              8
O1 :        3088.51 Hz
PULPROG : zgpr
SFO1 :    500.1330885 MHz
SOLVENT : CDCl3
SW :        20.6557 ppm
*** Processing Parameters ***
LB :           0.30 Hz
PHC0 :        278.941 degree























































































































































*** Acquisition  Parameters ***
BF1 :     75.4677490 MHz
LOCNUC : 2H
NS :          20538
O1 :        7924.11 Hz
PULPROG : zgpg30
SFO1 :     75.4756731 MHz
SOLVENT : CDCl3
SW :       238.2968 ppm
*** Processing Parameters ***
LB :           1.00 Hz
PHC0 :        127.078 degree





































































































































































































































































































































































































































































*** Acquisition  Parameters ***
BF1 :    500.2300000 MHz
LOCNUC : 2H
NS :             16
O1 :        2751.27 Hz
PULPROG : zg
SFO1 :    500.2327513 MHz
SOLVENT : CDCl3
SW :        15.0080 ppm
*** Processing Parameters ***
LB :           0.10 Hz
PHC0 :        501.651 degree






















































































































































*** Acquisition  Parameters ***
BF1 :    125.7577890 MHz
LOCNUC : 2H
NS :           5282
O1 :       13204.57 Hz
PULPROG : zgpg30
SFO1 :    125.7709936 MHz
SOLVENT : CDCl3
SW :       238.7675 ppm
*** Processing Parameters ***
LB :           1.00 Hz
PHC0 :        181.469 degree









































































































































































































































































































































































































*** Acquisition  Parameters ***
BF1 :    500.2300000 MHz
LOCNUC : 2H
NS :              8
O1 :        2751.27 Hz
PULPROG : zg
SFO1 :    500.2327513 MHz
SOLVENT : CDCl3
SW :        15.0080 ppm
*** Processing Parameters ***
LB :           0.10 Hz
PHC0 :        489.836 degree
































































































































































*** Acquisition  Parameters ***
BF1 :    100.6127690 MHz
LOCNUC : 2H
NS :          12000
O1 :       11067.40 Hz
PULPROG : zgpg30
SFO1 :    100.6238364 MHz
SOLVENT : CDCl3
SW :       238.8943 ppm
*** Processing Parameters ***
LB :           1.00 Hz
PHC0 :        101.319 degree



















































































































































































































































































































































































































































































*** Acquisition  Parameters ***
BF1 :    500.2300000 MHz
LOCNUC : 2H
NS :              8
O1 :        2751.27 Hz
PULPROG : zg
SFO1 :    500.2327513 MHz
SOLVENT : CDCl3
SW :        15.0080 ppm
*** Processing Parameters ***
LB :           0.10 Hz
PHC0 :        399.897 degree






































































































































































*** Acquisition  Parameters ***
BF1 :    100.6127690 MHz
LOCNUC : 2H
NS :           3500
O1 :       11067.40 Hz
PULPROG : zgpg30
SFO1 :    100.6238364 MHz
SOLVENT : CDCl3
SW :       238.8943 ppm
*** Processing Parameters ***
LB :           1.00 Hz
PHC0 :         89.356 degree





























































































































































































































































































































































































































































































*** Acquisition  Parameters ***
BF1 :    400.1300000 MHz
LOCNUC : 2H
NS :              8
O1 :        2470.97 Hz
PULPROG : zg30
SFO1 :    400.1324710 MHz
SOLVENT : CDCl3
SW :        20.5524 ppm
*** Processing Parameters ***
LB :           0.30 Hz
PHC0 :        -46.426 degree


















































































































































*** Acquisition  Parameters ***
BF1 :    100.6127690 MHz
LOCNUC : 2H
NS :          12000
O1 :       11067.40 Hz
PULPROG : zgpg30
SFO1 :    100.6238364 MHz
SOLVENT : CDCl3
SW :       238.8943 ppm
*** Processing Parameters ***
LB :           1.00 Hz
PHC0 :         85.425 degree


































































































































































































































































































































































































































































































*** Acquisition  Parameters ***
BF1 :    500.1300000 MHz
LOCNUC : 2H
NS :              8
O1 :        3088.51 Hz
PULPROG : zgpr
SFO1 :    500.1330885 MHz
SOLVENT : CDCl3
SW :        20.6557 ppm
*** Processing Parameters ***
LB :           0.30 Hz
PHC0 :        277.889 degree

























































































































































*** Acquisition  Parameters ***
BF1 :     75.4677490 MHz
LOCNUC : 2H
NS :          21362
O1 :        7924.11 Hz
PULPROG : zgpg30
SFO1 :     75.4756731 MHz
SOLVENT : CDCl3
SW :       238.2968 ppm
*** Processing Parameters ***
LB :           1.00 Hz
PHC0 :        128.478 degree





























































































































































































































































































































































































































*** Acquisition  Parameters ***
BF1 :    500.1300000 MHz
LOCNUC : 2H
NS :            100
O1 :        3088.51 Hz
PULPROG : zg30
SFO1 :    500.1330885 MHz
SOLVENT : CD2Cl2
SW :        20.6557 ppm
*** Processing Parameters ***
LB :           0.30 Hz
PHC0 :         55.237 degree







































































































































































*** Acquisition  Parameters ***
BF1 :    125.7577890 MHz
LOCNUC : 2H
NS :          16744
O1 :       13204.57 Hz
PULPROG : zgpg30
SFO1 :    125.7709936 MHz
SOLVENT : CD2Cl2
SW :       238.7675 ppm
*** Processing Parameters ***
LB :           1.00 Hz
PHC0 :        192.400 degree

























































































































































































































































































































































































































































































*** Acquisition  Parameters ***
BF1 :    400.1300000 MHz
LOCNUC : 2H
NS :              8
O1 :        2470.97 Hz
PULPROG : zg30
SFO1 :    400.1324710 MHz
SOLVENT : CDCl3
SW :        20.5524 ppm
*** Processing Parameters ***
LB :           0.30 Hz
PHC0 :        -49.921 degree




































































































































*** Acquisition  Parameters ***
BF1 :    100.6127690 MHz
LOCNUC : 2H
NS :          12000
O1 :       11067.40 Hz
PULPROG : zgpg30
SFO1 :    100.6238364 MHz
SOLVENT : CDCl3
SW :       238.8943 ppm
*** Processing Parameters ***
LB :           1.00 Hz
PHC0 :         99.598 degree
























































































































































































































































































































































































































































































*** Acquisition  Parameters ***
BF1 :    500.1300000 MHz
LOCNUC : 2H
NS :             16
O1 :        3088.51 Hz
PULPROG : zg30
SFO1 :    500.1330885 MHz
SOLVENT : CDCl3
SW :        20.6557 ppm
*** Processing Parameters ***
LB :           0.30 Hz
PHC0 :         10.953 degree



















































































































































*** Acquisition  Parameters ***
BF1 :    125.7577890 MHz
LOCNUC : 2H
NS :          13491
O1 :       13204.57 Hz
PULPROG : zgpg30
SFO1 :    125.7709936 MHz
SOLVENT : CDCl3
SW :       238.7675 ppm
*** Processing Parameters ***
LB :           1.00 Hz
PHC0 :         12.940 degree


















































































































































































































































































































































































































*** Acquisition  Parameters ***
NS :              8
O1 :        3088.51 Hz
PULPROG : zg30
SFO1 :    500.1330885 MHz
SOLVENT : CDCl3
SW :        20.6557 ppm
*** Processing Parameters ***
LB :           0.30 Hz
















































































































































































*** Acquisition  Parameters ***
NS :          10576
O1 :       13204.57 Hz
PULPROG : zgpg30
SFO1 :    125.7709936 MHz
SOLVENT : CDCl3
SW :       238.7675 ppm
*** Processing Parameters ***
LB :           1.00 Hz






























































































































































































































































































































































































































*** Acquisition  Parameters ***
BF1 :    500.1300000 MHz
LOCNUC : 2H
NS :              8
O1 :        3088.51 Hz
PULPROG : zg30
SFO1 :    500.1330885 MHz
SOLVENT : CDCl3
SW :        20.6557 ppm
*** Processing Parameters ***
LB :           0.30 Hz
PHC0 :         58.500 degree











































































































































































































*** Acquisition  Parameters ***
BF1 :    125.7577890 MHz
LOCNUC : 2H
NS :           3625
O1 :       13204.57 Hz
PULPROG : zgpg30
SFO1 :    125.7709936 MHz
SOLVENT : CDCl3
SW :       238.7675 ppm
*** Processing Parameters ***
LB :           1.00 Hz
PHC0 :        156.594 degree




















































































































































































































































































































































































































































































*** Acquisition  Parameters ***
BF1 :    500.1300000 MHz
LOCNUC : 2H
NS :              8
O1 :        3088.51 Hz
PULPROG : zg30
SFO1 :    500.1330885 MHz
SOLVENT : CDCl3
SW :        20.6557 ppm
*** Processing Parameters ***
LB :           0.30 Hz
PHC0 :         19.904 degree

























































































































































*** Acquisition  Parameters ***
BF1 :    125.7577890 MHz
LOCNUC : 2H
NS :           2661
O1 :       13204.57 Hz
PULPROG : zgpg30
SFO1 :    125.7709936 MHz
SOLVENT : CDCl3
SW :       238.7675 ppm
*** Processing Parameters ***
LB :           1.00 Hz
PHC0 :         29.153 degree




































































































































































































































































































































































































*** Acquisition  Parameters ***
BF1 :    500.1300000 MHz
LOCNUC : 2H
NS :             16
O1 :        3088.51 Hz
PULPROG : zg30
SFO1 :    500.1330885 MHz
SOLVENT : CDCl3
SW :        20.6557 ppm
*** Processing Parameters ***
LB :           0.30 Hz
PHC0 :          6.454 degree

























































































































































































































































































































































































































































































*** Acquisition  Parameters ***
BF1 :    500.1300000 MHz
LOCNUC : 2H
NS :             16
O1 :        3088.51 Hz
PULPROG : zg30
SFO1 :    500.1330885 MHz
SOLVENT : CDCl3
SW :        20.6557 ppm
*** Processing Parameters ***
LB :           0.30 Hz
PHC0 :          8.692 degree

































































































































































































































































































































































*** Acquisition  Parameters ***
BF1 :    500.1300000 MHz
LOCNUC : 2H
NS :              8
O1 :        3088.51 Hz
PULPROG : zg30
SFO1 :    500.1330885 MHz
SOLVENT : CDCl3
SW :        20.6557 ppm
*** Processing Parameters ***
LB :           0.30 Hz
PHC0 :         55.536 degree











































































































































*** Acquisition  Parameters ***
BF1 :    125.7577890 MHz
LOCNUC : 2H
NS :           1325
O1 :       13204.57 Hz
PULPROG : zgpg30
SFO1 :    125.7709936 MHz
SOLVENT : CDCl3
SW :       238.7675 ppm
*** Processing Parameters ***
LB :           1.00 Hz
PHC0 :        167.201 degree














































































































































*** Acquisition  Parameters ***
BF1 :    125.7577890 MHz
LOCNUC : 2H
NS :             99
O1 :       13204.57 Hz
PULPROG : zgpg30
SFO1 :    125.7709936 MHz
SOLVENT : CDCl3
SW :       238.7675 ppm
*** Processing Parameters ***
LB :           1.00 Hz
PHC0 :        136.474 degree











































































































































































































































































































































































*** Acquisition  Parameters ***
BF1 :    500.2300000 MHz
LOCNUC : 2H
NS :              8
O1 :        2751.27 Hz
PULPROG : zg
SFO1 :    500.2327513 MHz
SOLVENT : CDCl3
SW :        15.0080 ppm
*** Processing Parameters ***
LB :           0.10 Hz
PHC0 :        406.766 degree






































































































































*** Acquisition  Parameters ***
BF1 :    125.7577890 MHz
LOCNUC : 2H
NS :            111
O1 :       13204.57 Hz
PULPROG : zgpg30
SFO1 :    125.7709936 MHz
SOLVENT : CDCl3
SW :       238.7675 ppm
*** Processing Parameters ***
LB :           1.00 Hz
PHC0 :        222.065 degree








































































































































































































































































































































































































































































































*** Acquisition  Parameters ***
BF1 :    500.2300000 MHz
LOCNUC : 2H
NS :             16
O1 :        2751.27 Hz
PULPROG : zg
SFO1 :    500.2327513 MHz
SOLVENT : CDCl3
SW :        15.0080 ppm
*** Processing Parameters ***
LB :           0.10 Hz
PHC0 :        524.122 degree






















































































































































*** Acquisition  Parameters ***
BF1 :    100.6127690 MHz
LOCNUC : 2H
NS :          12000
O1 :       11067.40 Hz
PULPROG : zgpg30
SFO1 :    100.6238364 MHz
SOLVENT : CDCl3
SW :       238.8943 ppm
*** Processing Parameters ***
LB :           1.00 Hz
PHC0 :         85.988 degree






































X-ray Structure of 383. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
